Introduction {#s1}
============

Eukaryotic cells partition biosynthetic, catabolic, and information processing activities into specialized organelles. To move materials among organelles while maintaining compartmental identity, specific cargos are picked and packaged into vesicular carriers. These carriers must accurately dock at and fuse with target organelles ([@bib3]; [@bib6]; [@bib69]; [@bib75]). Most intracellular fusion events are driven by the concerted folding and oligomerization --- zippering --- of SNARE proteins embedded in trans on the two apposed membranes. SNAREs confer inherent compartmental selectivity. Among the many possible permutations of SNARE complexes, only a subset assemble into kinetically stable complexes; among these, only a further subset efficiently initiate fusion ([@bib25]; [@bib40]).

Trans-SNARE zippering, membrane fusion, and cis-SNARE disassembly together constitute the SNARE cycle. The folded portion of a SNARE complex is a parallel bundle of four α-helical SNARE domains (Qa, Qb, Qc, and R; [@bib17]; [@bib21]; [@bib51]; [@bib67]). N-to-C zippering of the trans-SNARE complex generates mechanical tension ([@bib21]; [@bib32]; [@bib43]; [@bib85]), driving the SNARE C-termini and their associated membranes together to initiate lipid mixing and fusion. After fusion, the SNARE complex membrane anchors lie in cis, adjacent and parallel within the membrane. Cis-complexes are then disassembled to recycle and energize the SNAREs for subsequent fusion reactions ([@bib21]; [@bib39]). Disassembly requires the Sec18 ATPase and Sec17, an adapter that docks Sec18 onto the SNARE complex ([@bib21]; [@bib39]; [@bib68]; [@bib80]). In mammals, Sec18 and Sec17 are named NSF and α-SNAP. Here, we use the yeast nomenclature.

Assembly of the pre-fusion trans-SNARE complex is precisely choreographed by tethering and docking factors ([@bib3]; [@bib6]; [@bib75]). Diverse factors operate at specific compartments, but all SNARE-mediated fusion events that have been closely examined require cofactors of the Sec1/Mammalian UNC-18 (SM) family ([@bib6]; [@bib12]; [@bib69]). In vitro, SM proteins increase the rate of fusion several-fold above the basal rate catalyzed by SNAREs alone ([@bib18]; [@bib62]). In vivo, however, SM deletion annihilates fusion ([@bib12]; [@bib69]). It has been unclear whether SM proteins increase the rate or precision of SNARE assembly, make already-formed trans-complexes more fusogenic, or both.

Here, we examine SM function in the context of the HOPS tethering complex, which controls endolysosomal docking and fusion ([@bib55]; [@bib60]). Importantly, the HOPS SM subunit Vps33 is both necessary and sufficient for HOPS interaction with SNARE domains and SNARE complexes ([@bib16]; [@bib27]; [@bib34]; [@bib33]). A pair of breakthrough crystal structures seems to reveal how the Qa- and R-SNARE interact with Vps33 in a pre-fusion state ([@bib5]). These structures strongly support the hypothesis that Vps33 nucleates and guides assembly of the partially zipped trans-SNARE complex. The same mechanism may be common to all SMs.

The disassembly adapter Sec17 interacts not only with post-fusion SNARE complexes, but also with pre-fusion SNARE complexes as well ([@bib8]; [@bib48]; [@bib59]; [@bib64]; [@bib74]; [@bib77]; [@bib84]). In an apparent paradox, Sec17 has been reported to both inhibit and stimulate fusion. The fusion-augmenting activity of Sec17 was first observed in cell-free assays with intact native yeast vacuoles bearing stalled, partially zipped SNARE complexes ([@bib59]). To explain these unexpected results, we proposed that binding of Sec17 to trans-SNARE complexes stabilizes the folded state of the trans-SNARE complex's membrane-proximal C-terminal domain ([@bib59]). More recently, single-molecule force spectroscopy experiments provided direct evidence for this zipper-clamp mechanism ([@bib37]). Experiments with proteoliposomes demonstrated that Sec18, either with or without ATP hydrolysis, further enhances the Sec17 stimulation of fusion. Moreover, membrane penetration by a hydrophobic loop near the Sec17 N-terminus may contribute to Sec17's fusogenic activity ([@bib64]; [@bib84]).

In reconstitution experiments, SM activity becomes essential in the presence of molecular crowding agents ([@bib18]; [@bib78]) or in the presence of Sec17 and Sec18 ([@bib35]; [@bib42]; [@bib65]). Sec17 and SMs can physically associate with one another on quaternary SNARE complexes, and SNARE-bound Golgi or vacuole SM proteins directly impede Sec18-mediated SNARE disassembly ([@bib34]), conferring resistance to Sec18-mediated trans-complex disassembly ([@bib23]; [@bib77]). However, the functional interplay among Sec17, SMs, and the zippering trans complex has not been fully explored. The apparent paradox that Sec17 both inhibits and stimulates fusion is unresolved, and the ability of Sec17 to augment the fusion activity of trans-SNARE complexes has not been tested in vivo.

Here, we report parallel experiments in three systems: in vitro assays, with either synthetic chemically defined reconstituted proteoliposomes (RPLs) or with intact vacuolar lysosomes, and in vivo genetic tests in *Saccharomyces cerevisiae*. We find that SNARE zippering can be precisely manipulated to yield on-pathway trans-complexes that exhibit a range of fusogenic activities. We demonstrate that Sec17 functionally interacts with SNARE complexes before as well as after fusion, and we show that the functional consequences of Sec17-SNARE interactions are in turn regulated by HOPS and Vps33. In parallel studies ([@bib64]), we used the synthetic RPL system to demonstrate that Sec18 can augment Sec17 and trans*-*SNARE complex function, in the complete absence of Sec18 ATP hydrolysis or SNARE disassembly.

Results {#s2}
=======

Qc zippering beyond layer +5 drives fusion in vivo {#s2-1}
--------------------------------------------------

The Qc-SNARE Vam7 is essential for fusion of yeast lysosomal vacuoles. Vam7 is soluble and lacks a transmembrane anchor ([@bib13]; [@bib58]). Previously, we studied Vam7 C-terminal truncation mutants in vitro (Qc-∆ proteins; [Figure 1](#fig1){ref-type="fig"}). A subset of the Qc-∆ mutants assembled into partially zipped, stalled trans-SNARE complexes, in a docking reaction that required the vacuole Rab7 homolog Ypt7 ([@bib59]). To test whether Qc-∆ SNAREs function in vivo as they do in vitro, we studied cells expressing representative Qc-∆ truncation mutants.

![The set of Qc-∆ truncation mutants, mapped onto the structure of a quaternary SNARE bundle.\
The C-terminus of each Qc-∆ is indicated with boldface type, except for Qc1∆, which contains one additional aminoacyl residue that remains after cleavage of the C-terminal affinity tag used for purification. The transmembrane anchors of the Qa, Qb, and R-SNAREs are not depicted.](elife-27396-fig1){#fig1}

Wild-type yeast cells have 1--5 large vacuoles (class A morphology). Fusion-defective mutants such as *vam7*∆ have numerous fragmented vacuoles (class B; [@bib52]; [@bib73]). The Qc-∆ mutants were introduced through allelic exchange at the chromosomal *VAM7* locus or were overproduced from high-copy plasmids. Vacuoles were visualized using pulse-chase labeling with the vital dye FM4-64 ([@bib72]). Consistent with previous in vitro experiments ([@bib59]), Qc-wt or Qc-7∆ knock-in cells had morphologically normal vacuoles ([Figure 2A](#fig2){ref-type="fig"}), while Qc-1∆, Qc-3∆, Qc-5∆ knock-in cells had fragmented vacuoles and were phenotypically indistinguishable from the *vam7*∆ null mutant. Overproduction of Qc-1∆, −3∆, or −5∆ proteins in *vam7*∆ cells (which lack Qc-wt) also resulted in complete vacuolar fragmentation ([Figure 2B](#fig2){ref-type="fig"}, top row). Previously, we reported that in vitro, Qc-3∆ and Qc-5∆ nucleate stalled trans-SNARE complexes, while Qc-1∆ does not enter stable trans-SNARE complexes ([@bib59]). Consistent with the in vitro experiments, in wild-type *VAM7* cells overproduction of Qc-3∆ or Qc-5∆, but not Qc-1∆, caused dominant fragmentation of the vacuole with 30--40% penetrance ([Figure 2B](#fig2){ref-type="fig"}, bottom row). The partially penetrant phenotype likely reflects cell-to-cell variation in plasmid copy number.

![Characterization of Qc-∆ zippering mutants in vivo.\
(**A and B**) Vacuoles were labeled by pulse-chase loading with the styryl dye FM4-64, and observed by wide-field epifluorescence microscopy. Defects in vacuole morphology are quantified in the graphs to the right. 106--411 cells of each genotype were scored in at least two independent experiments. (**C and D**) Cargo trafficking defects of Qc-∆ mutants. Cell lysates were prepared and separated by SDS-PAGE, then analyzed by immunoblot using polyclonal antibodies against Vam7 (Qc), or monoclonal antibodies against ALP or CPY. Polyclonal anti-actin was used for the loading controls. The slower-than-expected migration of Qc-5∆ was also observed with recombinant Qc-5∆ purified from *E. coli* cells. A non-specific band in the Vam seven blots was present in lysates from all strains including *vam7∆* null mutants and is indicated by (\*). (**E and F**) Overproduction of Qc-5∆ causes dominant partial accumulation of AP-3 vesicles. In some cells, the vacuole is not fragmented, and AP-3 vesicles (Apl5-GFP punctae) accumulate at the vacuole limiting membrane, as shown in panel E. In panel F, AP-3 vesicles are quantified (Mann-Witney *U* test; n = 100 cell profiles per strain in two independent experiments). Scale bars (A,B,E) indicate 2 µm.](elife-27396-fig2){#fig2}

In addition to homotypic fusion, Vam7 mediates heterotypic fusion of vesicular carriers with the vacuole. We monitored two pathways using representative cargo proteins. Alkaline phosphatase (ALP) traffics directly from Golgi to vacuole, while carboxypeptidase Y (CPY) traffics from the Golgi to the vacuole via late endosomes. Both ALP and CPY traffic as inactive proenzymes that are cleaved and activated upon arrival at the vacuole. Fusion defects cause slow-migrating pro-forms (pALP and pCPY) to accumulate. Cells expressing Qc-1∆, −3∆, or −5∆ as knock-ins at the chromosomal *VAM7* locus had ALP and CPY maturation defects as severe as the *vam7*∆ null mutant ([Figure 2C](#fig2){ref-type="fig"}, compare lane 2 to lanes 5--7). Similar defects were evident when Qc-1∆, −3∆, or −5∆ were overproduced from high-copy plasmids in *vam7*∆ cells lacking Qc-wt ([Figure 2D](#fig2){ref-type="fig"}, lanes 12--14).

In *VAM7* wild-type cells, Qc-3∆ or Qc-5∆ overproduction caused dominant, partial defects in ALP maturation ([Figure 2D](#fig2){ref-type="fig"}, lanes 18 and 19). pALP is carried from the Golgi to the vacuole in vesicles bearing the AP-3 coat complex ([@bib15]). When docking and fusion at the vacuole are impaired, AP-3 vesicles accumulate ([@bib2]; [@bib53]). In wild-type cells overproducing Qc-5∆, the median number of AP-3 vesicles nearly doubled ([Figure 2E,F](#fig2){ref-type="fig"}). Qualitatively similar accumulations of AP-3 vesicles were observed in Qc-3∆ overproducers. Moreover, in Qc-5∆-overproducer cells, AP-3 puncta were observed in clumps at the vacuole-limiting membrane ([Figure 2E](#fig2){ref-type="fig"}, arrow), rather than dispersed throughout the cytoplasm as in *vam7∆* cells (lacking the vacuolar Qc). This suggests a defect in fusion but not docking. Moreover, it further suggests that the AP-3 vesicle coat does not dissociate until after zippering of the SNARE C-terminal domain, and perhaps following fusion ([@bib2]). Taken together, our in vivo results are consistent with previous in vitro studies of Qc-∆ mutants using native vacuoles ([@bib59]).

Sec17 interacts with partially zipped SNAREs to control fusion {#s2-2}
--------------------------------------------------------------

To see if we could detect additional functional states during SNARE zippering, we characterized additional Qc-∆ truncation mutants using the cell-free assay of vacuole homotypic fusion. This assay employs enzymatic complementation to quantify luminal content mixing when native lysosomal vacuoles fuse with one another ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). We first tested the Qc-∆ mutants in gain-of-function 'ATP bypass' assays. In this reaction, configuration ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, reaction ii), unpaired vacuolar Qa, Qb, and R-SNAREs drive Rab- and HOPS-dependent fusion when the recombinant Qc-SNARE is added. There is no requirement for added Sec17, Sec18, or ATP. ([@bib10]; [@bib41]; [@bib59]; [@bib70]). Unlike Qc-wt, neither Qc-2∆ nor Qc-4∆ drove fusion, even when added at high concentrations ([Figure 3A](#fig3){ref-type="fig"}). To evaluate whether Qc-2∆ and Qc-4∆ entered trans-complexes, like Qc-3∆, or failed to enter trans-complexes, like Qc-1∆, we assayed competitive inhibition of fusion reactions driven by endogenous Qc-wt ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, reaction i). In these assays, Mg·ATP activates Sec17- and Sec18-dependent disassembly of cis-SNARE complexes on the isolated vacuoles, liberating native Qc-wt (Vam7) to drive fusion. Here, added Qc-2∆, like Qc-1∆, was weakly inhibitory, while Qc-4∆, like Qc-3∆, was a potent competitive inhibitor ([Figure 3B](#fig3){ref-type="fig"}). We infer that Qc-4∆, like Qc-3∆ ([@bib59]; [@bib77]), enters into partially zipped but fusion-defective trans-SNARE complexes.

![Interplay of SNARE zippering and Sec17 in cell-free assays of homotypic vacuole fusion.\
The content-mixing assay and reaction schemes are diagrammed in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}. Curves in the dose-response and dose-inhibition experiments are nonlinear fits of the Hill equation. Dashed lines denote data re-plotted from [@bib59] to facilitate comparison. For all panels, points and bars denote the mean (+or ± s.e.m.) of ≥3 independent experiments. (**A**) Recombinant Qc-2∆, Qc-3∆, and Qc-4∆ proteins are nonfusogenic in no-ATP 'bypass' gain-of-function assays. In these assays no ATP, Sec17, or Sec18 are added to the vacuoles (as shown in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, reaction ii). The approximate concentration of endogenous cytoplasmic Vam7 in vivo is indicated ([@bib70]). (**B**) Qc-3∆ and Qc-4∆ are efficient competitive inhibitors of native Qc-wt. In these ATP-containing reactions, endogenous Sec17 and Sec18 are active and fusion is driven by native Qc-wt (Vam7) liberated from cis*-*SNARE complexes on isolated vacuoles, as diagrammed in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, reaction i. The approximate concentration of native Vam7 in a standard +ATP vacuole fusion reaction is indicated (\~16 nM; [@bib70]). (**C**) Added Sec17 restores fusion activity to Qc-3∆ and −4∆ in no-ATP 'bypass' assays. The reactions were set up as in panel A, except that the reactions were supplemented with 300 nM Sec17. (**D**) Sequence alignment of SNAREs in the layer +4 to+5 region. S.c., *Saccharomyces cerevisiae*; H.s., *Homo* sapiens; D.m., *Drosophila melanogaster*. A conserved arginyl (R) residue is indicated in red. (**E**) Ability of Qc-5∆ variants to promote fusion in no-ATP 'bypass' assays. The reactions were set up as in panel A. (**F**) Competitive inhibition of fusion by Qc-5∆ variants. The reactions were set up as in panel B. (**G**) Sec17 rescue in gain of function assays with Qc-2∆, Qc-3∆, and Qc-5∆ variants. The no-ATP 'bypass' reactions were set up as in panel A, except that the Qc-∆ proteins were always used at 100 nM, and a subset of the reactions were supplemented with 300 nM Sec17, as indicated.](elife-27396-fig3){#fig3}

Sec17 addition restores the ability of Qc-3∆ to drive fusion in the absence of Sec18 or ATP ([@bib59]; [@bib64]). In no-ATP gain-of-function reactions containing added Sec17, Qc-4∆ drove fusion with a dose-response relationship indistinguishable from that of Qc-3∆ ([Figure 3C](#fig3){ref-type="fig"}). In marked contrast, Sec17 failed to rescue fusion in reactions containing Qc-2∆ (see [Figure 3G](#fig3){ref-type="fig"}).

Taken together, these results and previous work ([@bib59]) indicate that the propensity to form a metastable trans complex increases in a switch-like manner as the Qc-SNARE is extended from layer +2 to layer +3 or +4. Force spectroscopy studies show that in a 'half-zipped' state the neuronal R-SNARE is structured to approximately layer +2, and the t/Q-SNARE complex is structured to layer +4 ([@bib36]; [@bib43]; [@bib79]; [@bib85]). Thus, our findings with yeast vacuoles agree remarkably well with the force-spectroscopy results. With a stalled trans-complex zipped to Qc layer +3 or +4, the docked membranes should be separated by 8--10 nm, fully hydrated and unable to initiate lipid mixing. The propensity of the partially zipped trans-complex to initiate fusion increases abruptly, either when Sec17 is added or by extending Qc-4∆ a single α-helical turn, from +4 to+5 ([Figure 3C,E](#fig3){ref-type="fig"}). Fusion is maximal when the Qc is extended to layer +7 ([@bib59]). Our results again are consistent with force spectroscopy experiments, where a transition barrier between the partially zipped state and C-terminal domain trans*-*complex zippering is traversed as R-SNARE assembly proceeds through layer +3,+4, or +5, depending on the specific complex ([@bib43]; [@bib85]).

The sharply increased in vitro fusion activity of Qc-5∆ versus Qc-4∆ prompted closer examination of the layer +5 region. Vam7 (Qc-wt) contains two arginyl (R) residues between layers + 4 and+5 ([Figure 3D](#fig3){ref-type="fig"}). The second residue is conserved in many Qc-SNAREs ([@bib17]; [@bib67]). In gain-of-function 'bypass' reactions lacking ATP ([Figure 3E](#fig3){ref-type="fig"}), mutation of the non-conserved first Arg to Ala (AR) slightly increased fusion versus 'wild-type'(RR) Qc-5∆. Mutation of the second, conserved Arg (RA) decreased fusion. Mutation of both residues (AA) further impaired fusion. In competition assays containing ATP, where fusion is driven by native Qc-wt, the abilities of the variants to dominantly impair fusion mirrored their activities in the gain-of function assays ([Figure 3F](#fig3){ref-type="fig"}; compare to 3E). Hence, these mutants are true partial agonists of fusion. In both assay configurations, the apparent K~M~ (EC~50~) values for the mutant Qc-5∆s (AR, RA, AA) were indistinguishable from 'wild-type' Qc-5∆ (RR). Thus, the ability of these Qc-5∆ mutants to assemble into pre-fusion complexes was unaltered, even as their capacity to drive fusion diverged. Moreover, added Sec17 allowed all Qc-5∆ variants to drive fusion with similar efficiency ([Figure 3G](#fig3){ref-type="fig"}). These findings, and results from other systems ([@bib17]; [@bib44]; [@bib57]) indicate that Qc layer +5 has a pivotal role in fusion, probably driving C-terminal zippering beyond the 'half-zipped' metastable state and through the transition barrier separating partially zipped and C-terminally zipped trans*-*complexes ([@bib32]; [@bib37]; [@bib43]; [@bib85]). As discussed below, the transition between the partially zipped and C-terminally zipped states likely also results in ejection of the bound SM cofactor Vps33. Our results with intact vacuoles also mirror force spectroscopy studies done in solution, which show that Sec17 (α-SNAP)-binding promotes zippering of the SNARE bundle's C-terminal domain ([@bib37]).

Sec17 can rescue partially zipped complexes in the complete absence of Sec18 {#s2-3}
----------------------------------------------------------------------------

To establish minimal requirements for Sec17 rescue of trans*-*complexes that were zipped to different extents, we used chemically defined reconstituted proteoliposomes (RPLs; ([@bib64]; [@bib83]; [@bib84]; [@bib86]). To negate the requirement for cis-SNARE complex disassembly by ATP and Sec18, the SNAREs were distributed asymmetrically as in the heterotypic fusion configuration ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). One set of RPLs displayed the Qa- and Qb-SNAREs Vam3 and Vti1; the other, the R-SNARE Nyv1. All RPLs displayed a GTP-loaded Rab, Ypt7. The concentrations of Vam7 (Qc), Sec17, and Sec18 were selected based on results obtained with native yeast vacuoles ([Figure 3](#fig3){ref-type="fig"}; [@bib59]; [@bib70]; [@bib71]). Lipid mixing and luminal aqueous content mixing were simultaneously monitored in each reaction using Förster resonance energy transfer (FRET) probes ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Both fusion read-outs yielded similar results. We therefore focus on content mixing, the reaction endpoint.

In reactions lacking Sec18, when HOPS and full-length Qc-wt were added to RPLs, fusion was rapid and efficient whether Sec17 was added to the reaction or not ([Figure 4A--C](#fig4){ref-type="fig"}). In contrast to Qc-wt, the truncation mutants Qc-3∆, −4∆, and −5∆ were non-fusogenic unless Sec17 was supplied ([Figure 4B,C](#fig4){ref-type="fig"}). In the absence of Sec17, Sec18 was unable to rescue Qc truncation mutants ([Figure 4A,D,G](#fig4){ref-type="fig"}). However, Sec18 dramatically enhanced Sec17-mediated rescue and allowed fusion with the Qc-∆ proteins, at much lower Sec17 concentrations ([Figure 4D--I](#fig4){ref-type="fig"}). Qc-5∆ always had more fusion activity than Qc-3∆ or Qc-4∆, underscoring the interplay between Sec17 stimulation and trans-SNARE zippering.

![Sec17 allows partially-zipped SNARE complexes to drive fusion with or without Sec18.\
The chemically defined RPL fusion system is diagrammed in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}. RPLs bearing Ypt7-GTP (Rab), and either the Qa- and Qb-SNARES, or the R-SNARE, were incubated with HOPS (100 nM) and the indicated Qc-SNAREs (250 nM). Reactions were performed in the absence or presence of Sec17 and Sec18, as indicated. 1 mM ATP and HOPS were present under all conditions. The Rab Ypt7 was present on both vesicle populations and was loaded with GTP (Materials and methods). On the vertical axes, 100% fusion indicates complete association of the FRET probes encapsulated within the two vesicle populations, as determined in control reactions. Each data point shows the mean content mixing signal ± s.e.m. for three independent experiments. The lines show nonlinear best-fits of a second-order kinetic model.](elife-27396-fig4){#fig4}

At this point, we can draw several conclusions. First, Sec17 rescue of partially zipped SNARE complexes can occur in the total absence of Sec18. This is consistent with our original vacuole experiments, where Sec17 rescued Qc-3∆ in the absence of ATP, even in the presence of inhibitory Sec18 antibodies or when a Sec17 mutant defective for Sec18 interaction was used ([@bib59]). In parallel work, we demonstrated that rigor-locked Sec18-ATP can augment the Sec17 rescue of Qc-3∆ without any requirement for ATP hydrolysis ([@bib64]). Thus, when present, Sec18 need not disassemble SNARE complexes to facilitate Sec17-mediated triggering of fusion. Second, full-length Vam7 (Qc-wt) might be available in residual quantities on intact vacuoles, but it is not present in the chemically defined Qc-∆ RPL reactions. Thus, Sec17 supports Qc-∆--mediated fusion in the total absence of full-length Qc-wt. Third, no additional vacuolar proteins are needed for Sec17 stimulation of fusion. Importantly, Sec17 stimulation of fusion is observed both with native vacuole membranes and with RPLs, even at physiological or below-physiological SNARE, Rab, and HOPS concentrations ([@bib59]; [@bib64]; [@bib84]).

Sec17 requirements for stimulation and inhibition of fusion {#s2-4}
-----------------------------------------------------------

In addition to the canonical role of Sec17 in cis-SNARE complex disassembly, and its ability to augment the fusion capacity of SNARE complexes, Sec17/α-SNAP has also been reported to inhibit fusion of yeast vacuoles and dense core secretory vesicles ([@bib48]; [@bib74]). To separate these divergent functions of Sec17, we analyzed a panel of Sec17 mutants. Sec17 interacts with SNARE proteins through a large concave binding surface, it interacts with Sec18 through its C-terminal domain, and it interacts with membranes through an N-terminal hydrophobic loop ([@bib7]; [@bib21]; [@bib30]; [@bib38]; [@bib59]; [@bib76]). Previously, we demonstrated that Sec17-LALA, a mutant impaired in its ability to stimulate Sec18 ATPase activity and SNARE disassembly ([@bib7]), exhibits enhanced inhibitory activity and stimulates SNARE-mediated fusion about as well as wild-type Sec17 ([@bib59]; [@bib64]; [@bib83]). Here, we focus on the interactions of Sec17 with SNAREs and with membranes.

To perturb the Sec17-SNARE-binding interface, we mutated two highly conserved Lys residues to Glu (K159E and K163E), alone or together ([Figure 5A](#fig5){ref-type="fig"}). K159 directly contacts the ionic 0-layer of the SNARE complex and contributes to efficient Sec18-mediated SNARE disassembly in vitro ([@bib38]; [@bib80]). In gain-of-function assays with Qc-∆3, Sec17-K159E stimulated fusion only at concentrations about 10-fold higher than the wild type, and to a lesser maximal extent. In contrast, Sec17-K163E supported fusion with Qc-∆3 just as well as the wild type. The double mutant ('KEKE') behaved like the K159E single mutant. K159 and K163 sit on adjacent α--helices with side chains separated by \~8 Å, yet charge substitutions at these positions have completely different effects. This selectivity suggests that ionic layer recognition by K159 could contribute to the Sec17 stimulation of fusion. Parallel studies of the two-site mutant Sec17-KEKE using chemically defined proteoliposomes ([@bib64]) are consistent with this interpretation.

![Effects of Sec17 mutations on stimulation of fusion.\
(**A**) Locations of Sec17 mutations. The diagram is a rendering of PDB 1QQE ([@bib54]). The N-terminal hydrophobic loop is shaded magenta. Two highly conserved lysine residues are shaded green. (**B**) Position of Sec17 hydrophobic loop relative to SNARE core complex. Rendering shows a SNARE complex with four bound α-SNAP molecules, from the perspective of the membrane-proxiimal SNARE domain C-termini. Hydrophobic loop residues are colored magenta. The two residues homologous to those mutated in Sec17-FSMS are circled. The rendering is based on PDB 3J96 ([@bib80]). (**C and D**) Ability of Sec17 mutants to rescue Qc-3∆ trans-SNARE complexes in vitro. Vacuole fusion reactions were assembled in the gain-of-function --ATP ('bypass') configuration ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, reaction ii), with 75 nM Qc-3∆ and the indicated concentrations of Sec17 or its mutants. Fusion is normalized relative to the signals from standard ATP-driven reactions without added Sec17. Each point denotes the mean ± s.e.m. of three independent experiments.](elife-27396-fig5){#fig5}

Sec17 and mammalian α-SNAP contain a flexible N-terminal loop ([Figure 5A,B](#fig5){ref-type="fig"}) bearing four hydrophobic residues that penetrate the phospholipid bilayer ([@bib76]). In experiments with synthetic RPLs, mutation of two residues (Sec17 F21S M22S; 'FSMS') nearly eliminated Sec17 stimulation of fusion ([@bib64]; [@bib84]). A similar defect was evident with Sec17-FSMS in assays using native vacuoles ([Figure 5D](#fig5){ref-type="fig"}). To further analyze the role of the hydrophobic loop, we studied four additional mutants: Sec17-RMKLR was designed to test whether the two aromatic residues in the loop are needed for stimulation of fusion; Sec17-RSKSR was designed to test whether positively charged residues that might interact with negatively charged lipids in the membrane could substitute for the hydrophobic residues; and the ∆21--25 and ∆1--25 mutants were constructed to test the effect of removing the entire hydrophobic loop, with or without the preceding N-terminal residues. Every loop mutant tested was dramatically impaired in its ability to stimulate fusion in the presence of Qc-∆3. Notably, however, at very high concentration (10 µM) Sec17-RMKLR had substantial stimulatory activity. This suggests that hydrophobicity in the loop contributes to Sec17 affinity but that the specific presence of aromatic residues (F21 and F25) is dispensable for Sec17 stimulation of fusion.

![Effects of Sec17 mutations on inhibition of fusion.\
(**A and B**) Ability of Sec17 mutants to inhibit standard ATP-driven vacuole fusion reactions. Vacuole fusion reactions were assembled in standard configuration with 1 mM ATP ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, reaction i), and the indicated concentrations of Sec17 or its mutants. Fusion is normalized relative to the signals from standard ATP-driven reactions without added Sec17. Each point denotes the mean ±s.e.m. of three independent experiments.](elife-27396-fig6){#fig6}

A notable feature of the Sec17 dose-response curves is a sharp peak in activity followed by a decrease in Qc-3∆ rescue at elevated Sec17 concentrations. High Sec17 concentrations can inhibit vacuole fusion in standard, ATP-driven reactions ([@bib74]). In assays performed under these conditions ([Figure 6](#fig6){ref-type="fig"}), wild-type Sec17 inhibited fusion with a dose response similar to that previously reported by Wang et al. The SNARE-interaction mutations K159E, K163E, and the two-site mutant (Sec17-KEKE) had inhibitory activity indistinguishable from wild type Sec17, indicating that inhibition does not require a specific interaction between Sec17 and the SNARE 0-layer. In marked contrast, mutations in the Sec17 hydrophobic loop caused dramatic losses of inhibitory activity, with IC~50~ values shifted rightward by 40- to 200-fold compared to the wild type. Together, the data show that the apolar loop of Sec17, and hence Sec17 interaction with the membrane, has a large effect on the ability of Sec17 to both inhibit and stimulate fusion.

Sec17 augments Qc-∆ SNARE function in vivo {#s2-5}
------------------------------------------

In vitro, Sec17 addition allows Qc-3∆, −4∆, or −5∆ to fuse vacuoles and RPLs ([Figure 3](#fig3){ref-type="fig"},[4](#fig4){ref-type="fig"},[5](#fig5){ref-type="fig"}). However, all Qc-∆ truncation mutants except Qc-7∆ have severe fusion defects in vivo, even when overproduced ([Figure 2](#fig2){ref-type="fig"}). Can elevated Sec17 or Sec18 levels suppress the functional defects of Qc-∆ SNAREs in living cells? To answer this question, we overproduced Sec17, Sec18, or both from high-copy plasmids. To verify that overproduced Sec17 and Sec18 are functional, we assayed vacuolar SNARE complex abundance by co-immunoprecipitation ([Figure 7A](#fig7){ref-type="fig"}). At steady state, only \~3% of SNARE complexes are in trans, so this approach assays the \~97% of complexes that are in cis. Sec18 overproduction, with or without Sec17 overproduction, decreased cis-complex abundance and decreased Sec17-SNARE association ([Figure 7A](#fig7){ref-type="fig"}, compare lanes 2,3 to 4,5). In contrast, Sec17 overproduction alone did not substantially alter either cis-complex abundance or Sec17-SNARE association ([Figure 7](#fig7){ref-type="fig"}, compare lanes 2 and 3). Comparable results were reported for experiments with *Drosophila* ([@bib4]; [@bib19]).

![Sec17 overproduction partially rescues in vivo activity of Qc-5∆.\
(**A**) Analysis of cis-SNARE complex abundance in lysates of cells overproducing Sec17 and Sec18. The top panel shows immunoblots of cell lysates. In the bottom panel, anti-Vam3 (Qa-SNARE) was immunoprecipitated from detergent lysates from the indicated strains under non-denaturing conditions. The precipitated material was separated by SDS-PAGE and analyzed by immunoblot, as indicated. IP, immunoprecipitate; FT, flow-through. PGK, phosphoglycerate kinase (control). Additional experimental details are provided in the Materials and methods. (**B**) Vacuoles in the indicated cell lines were labeled by pulse-chase with FM4-64 dye and observed by epifluorescence. (**C**) Quantification of phenotypes in B. Bars show mean scores from three independent experiments (n = 88--354 cells per genotype per experiment). (**D**) Vacuoles in the indicated cell lines were labeled by pulse-chase with FM4-64 dye and observed by epifluorescence. (**E**) Quantification of phenotypes in D. Bars show mean scores as in C.](elife-27396-fig7){#fig7}

Overproduction of Sec17, Sec18, or both together did not alter vacuole morphology in otherwise wild-type cells, and failed to rescue vacuole morphology in cells expressing Qc-3∆ or Qc-5∆ ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). There is, however, an important difference between the conditions in vivo and in vitro. In vivo, the vacuole-associated kinase Yck3 negatively regulates fusion by phosphorylating HOPS and the Rab GEF Mon1. These phosphorylation events impair both Ypt7 Rab activation and HOPS-membrane association ([@bib11]; [@bib28]; [@bib31]). Our Qc-∆/Sec17 rescue experiments with purified yeast vacuoles ([Figure 3](#fig3){ref-type="fig"},[5](#fig5){ref-type="fig"}) are done under 'bypass' conditions in the absence of ATP, resulting in Yck3 loss-of-function ([@bib11]; [@bib28]), and Yck3 is not present in the synthetic RPL reactions. Hence, we tested Qc-∆ function in *yck3*∆ mutant cells. In *yck3*∆ cells expressing either Qc-3∆ or Qc-5∆, vacuoles were uniformly fragmented, indicating that elevated HOPS activity does not by itself restore Qc-∆ function. However, overproduction of either Sec17, or Sec17 and Sec18 together, rescued Qc-5∆ vacuole morphology with \~20% penetrance ([Figure 7B,C](#fig7){ref-type="fig"}). The partial rescue of Qc-5∆ rescue makes sense. In cell-free assays of homotypic vacuole fusion, Sec17 augments Qc-∆ activity only over a narrow range of Sec17 concentrations ([Figure 5](#fig5){ref-type="fig"}). Because the copy number of yeast 2µ plasmids varies from cell to cell, partial rescue probably reflects variation in Sec17 expression. Qc-3∆ mutants exhibited severe defects in vivo under all conditions, consistent with the generally lower fusion activity of Qc-3∆ in vitro, with both vacuoles and RPLs. Sec17 overproduction alone had no influence on cis-SNARE complex abundance, and Sec18 overproduction alone did not rescue Qc-5∆ ([Figure 7B,C](#fig7){ref-type="fig"}). Overproduction of Sec17-FSMS failed to rescue vacuole morphology in *yck3∆ Qc-5*∆ cells ([Figure 7D,E](#fig7){ref-type="fig"}), indicating that the Sec17 hydrophobic loop is needed to augment Qc-∆ function in vivo as it is in vitro. Neither the rate of cis-SNARE complex disassembly, nor the steady-state availability of unpaired SNAREs, can explain why Sec17 augments Qc-5∆ function in vivo. The most likely remaining explanation is that Sec17 augments the fusion activity of partially zipped trans-complexes in vivo, just as it does in vitro.

Since *SEC17* is an essential gene ([@bib46]), we tested the ability of several Sec17 mutants to support viability. Among these, only Sec17-LALA, which is impaired in its ability to stimulate Sec18 ATPase activity ([@bib7]; [@bib59]; [@bib84]), was unable to support viability in *sec17-1* temperature-sensitive cells grown at the restrictive temperature of 37°C ([Figure 7---figure supplement 2](#fig7s1){ref-type="fig"}). Mutations in the hydrophobic loop or in the zero-layer-interacting residue K159 did not cause lethality. These results indicate that the Sec17-Sec18 interaction is essential for viability, but also demonstrate that the Sec17-Sec18 system is sufficiently robust that even relatively severe losses of Sec17 activity are tolerated in vivo.

Sec17 triggers fusion after trans-SNARE complex assembly {#s2-6}
--------------------------------------------------------

In the forward docking and fusion pathway, where does Sec17 act to stimulate fusion? To address this question, we set up staging experiments with intact vacuoles ([Figure 8](#fig8){ref-type="fig"}). Two reaction protocols were compared. In control reactions ([Figure 8A](#fig8){ref-type="fig"}), vacuoles were allowed to tether for 25 min. Trans-SNARE complex formation and fusion were then initiated by adding full-length Qc-wt. At various times before or after Qc-wt addition, inhibitors were added to the reactions. At all times up to −1 min before Qc addition (red dashed line), antibodies against the Rab, the SM, or the Qa-SNARE still partially or completely inhibited fusion. After Qc-wt addition, the reactions became resistant to these inhibitors within a couple of minutes. In a second set of reactions ([Figure 8B](#fig8){ref-type="fig"}), vacuoles were allowed to tether for 10 min. Qc-3∆ was then added and the reactions were incubated a further 15 min to allow trans-SNARE complex assembly. Finally, fusion was triggered by the addition of Sec17 (defined as t = 0). Before Qc-3∆ addition, antibodies against the Rab, the SM, or the Qa-SNARE largely or completely inhibited fusion. However, by −1 min before Sec17 addition (vertical red dashed line), and at subsequent time points, the reactions were insensitive to antibodies against the Rab, the HOPS SM subunit Vps33, and the Qa-SNARE Vam3. Qc-3∆ addition therefore drives the vacuoles into an operationally docked state. In this state, partially zipped trans-SNARE complexes have assembled ([@bib59]; [@bib77]), and Sec17 efficiently triggers fusion even when inhibitors of the Rab, the SM, or the Qa-SNARE are present. We conclude that once the SNAREs are partially zipped, the Rab, the SM, and the Qa-SNARE either are no longer required, or they are in a state that is efficiently shielded from inhibitory antibodies. The docked, trans-SNARE paired vacuoles could still be prevented from fusing, however, by a peptide inhibitor of fusion, the MARCKS effector domain (MED), up to the moment of Sec17 triggering.

![Staging of Sec17 rescue in cell-free assays of vacuole fusion.\
(**A**) Master vacuole fusion reactions were assembled under no-ATP 'bypass' conditions ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), and pre-incubated for 25 min at 27°C. Fusion was then initiated (**t~0~**) by adding Qc-wt to 20 nM final concentration. At the indicated time points, an aliquot was withdrawn from the master reaction and added to a tube containing the indicated inhibitor (or placed on ice), and incubated for the duration of the experiment. At t = 70 min, each reaction aliquot was assayed for content mixing. (**B**) Fusion reactions assembled under no-ATP 'bypass' conditions were pre-incubated for 10 min at 27°C. At t = −15 min, 75 nM Qc-3∆ was added and the reactions were incubated for an additional 15 min. Fusion was initiated by adding Sec17 (300 nM). At the indicated time points, an aliquot was withdrawn from the master reaction and added to a tube containing the indicated inhibitor (or placed on ice), and incubated for the duration of the experiment. At t = 70 min, each reaction aliquot was assayed for content mixing. For both panels, each point indicates mean + s.e.m. for two to six independent experiments.](elife-27396-fig8){#fig8}

We next used co-immunoprecipitations to examine the associations of Vps33/HOPS with SNARE proteins during a Qc-∆3 block/Sec17 rescue reaction like that in [Figure 8B](#fig8){ref-type="fig"}. Vacuoles lacking vacuolar protease activity (*pep4*∆) and bearing functional, GFP-tagged Vps33 were incubated with Qc-3∆ to establish partially zipped trans-SNARE complexes ([Figure 9A](#fig9){ref-type="fig"}). The vacuoles, now bearing partially zipped Qc-3∆ complexes, were then triggered by Sec17 addition, incubated for an additional 5 min, dissolved in nonionic detergent, and subjected to immunoprecipitation to retrieve Vps33-GFP and any associated proteins. As expected, Vps33 associated with Vps41, another HOPS subunit, under all conditions tested. Upon Qc-3∆ addition, Vps33/HOPS bound to the Qa- and R-SNAREs (compare lanes 1 and 2). In previous work ([@bib59]), we demonstrated that inhibition of the Ypt7 Rab by GDI prevents Qc-3--driven trans-SNARE complex assembly. Here, GDI addition 1 min prior to Qc-3∆ addition prevented association of the Qa, Qc, and R-SNAREs with Vps33 (lane 3). In contrast, addition of GDI after Qc-3∆ addition and trans-SNARE assembly did not cause the SNAREs to dissociate from Vps33/HOPS (lane 4). Thus, the Rab is needed both for Vps33/HOPS association with the SNARE proteins, and for assembly of the partially zipped trans-SNARE complex. Triggering of fusion by Sec17 addition (lane 5) caused ejection of Vps33/HOPS from the SNARE complex. This experiment cannot distinguish whether Vps33/HOPS dissociation from the SNAREs occurs prior to, during, or after the fusion event itself. However, structural studies of Vps33 suggest that Vps33 facilitates N-to-C zippering trans*-*SNARE complexes until they are in a partially zipped state, and imply that Vps33 must then dissociate for the completion of SNARE zippering and fusion ([@bib5]). Such a model is corroborated by laser tweezers experiments with Munc-18 and neuronal SNAREs the absence of membranes ([@bib36]). This model predicts that Vps33 should bind to quaternary SNARE complexes in solution more readily if the Qa and R-SNAREs have splayed C-terminal domains. To test this prediction, we assembled quaternary complexes of vacuolar SNARE cytoplasmic domains with either Qc-wt or Qc-5∆, and tested their ability to bind purified monomeric Vps33. Vps33-bound Qc-5∆ complexes more efficiently than Qc-wt complexes ([Figure 9B](#fig9){ref-type="fig"}).

![Sec17 and SNARE zippering regulate SNARE interactions with HOPS and Vps33.\
(**A**) Analysis of HOPS-SNARE interactions during a Qc-3∆ block and Sec17 rescue. No-ATP 'bypass' reactions were set up similarly to the fusion reactions in [Figure 8B](#fig8){ref-type="fig"}, except that only vacuoles isolated from protease-deficient cells expressing Vps33-GFP were used. The vacuoles were pre-incubated for 10 min at 27°C. Qc-3∆ (75 nM) was then added to initiate the assembly of partially zipped trans-complexes. The reactions were incubated for an additional 10 min, and fusion was triggered by adding Sec17 (300 nM). The Rab inhibitor GDI (2.4 µM) was added at early (E) or late (L) time points (lanes 3 and 4). 5 min after Sec17 addition, the vacuoles were sedimented and dissolved in nonionic detergent, and Vps33-GFP was immunoprecipitated with anti-GFP antibodies. The precipitates were separated by SDS-PAGE and analyzed by immunoblot. (**B**) Interactions of purified Vps33 monomer with vacuolar SNARE complexes. Complexes containing either Qc-wt or Qc-5∆, or the Golgi SNARE Sso1 (control) were assembled on glutathione-agarose resin, and used in pulldowns with soluble, purified recombinant Vps33 as described previously ([@bib34]). After washing, the resin-associated material was separated by SDS-PAGE and analyzed either by immunoblotting for Vps33-GFP or by Coomassie blue staining. The band intensities for Vps33 were quantified in three independent experiments and are plotted as mean ± s.e.m.](elife-27396-fig9){#fig9}

Together, the findings in [Figures 8](#fig8){ref-type="fig"} and [9](#fig9){ref-type="fig"} show that Sec17 need not be present during tethering or docking, that it can act to trigger fusion after docking is complete, and that following Sec17 addition, Vps33 dissociates from the SNAREs, likely before or during C-terminal SNARE zippering (and therefore prior to fusion). Moreover, the data imply, but do not prove, that Sec17 might be able to trigger fusion by binding to partially zipped SNARE complexes in the complete absence of HOPS and Vps33. To further test this working model in a system allowing tighter experimental control, we returned to chemically defined RPLs.

HOPS selects the outcome of Sec17--SNARE interactions {#s2-7}
-----------------------------------------------------

HOPS promotes efficient tethering, docking, and trans-SNARE pairing ([@bib5]; [@bib66]; [@bib83]). To test how HOPS influences the function of Sec17 during docking and fusion, parallel reactions were initiated with Qab-SNARE RPLs, R-SNARE RPLs, and Qc-wt in the absence or presence of Sec17, as well as in the absence or presence of HOPS. In the absence of HOPS, the normal HOPS/SM requirement in vesicle tethering and trans-SNARE assembly was bypassed by adding 2% polyethylene glycol (PEG; [@bib24]; [@bib83]). Full-length Qc-wt drove efficient fusion in the presence of HOPS, and this fusion was unaffected or slightly stimulated by Sec17 ([Figure 10A](#fig10){ref-type="fig"}). In marked contrast, in no-HOPS reactions containing PEG, Sec17 strongly impaired fusion ([Figure 10B](#fig10){ref-type="fig"}). Inhibition of fusion by Sec17, or by Sec17 and Sec18 together, has been reported with native vacuoles, and with both vacuolar and secretory in vitro reconstitution systems ([@bib35]; [@bib48]; [@bib74]; [@bib77]). In vivo, moreover, overproduced Sec17 is tolerated in otherwise wild-type cells, but excess Sec17 is toxic when SM function (either Vps33 or Sly1) is partially impaired ([@bib34]). Each of these findings supports the interpretation that HOPS, and in particular the SM subunit Vps33, facilitates fusion in the presence of otherwise inhibitory Sec17.

![HOPS-SM gates Sec17 function.\
(**A and B**) RPLs bearing Ypt7:GTP and either the Qa and Qb SNAREs, or the R SNARE, were incubated with Sec17 (0 or 600 nM) and Qc-wt (80 and 400 nM in panel A and B, respectively). In panel A, HOPS was present (100 nM). In panel B, the HOPS requirement was bypassed by adding 2% PEG. In control reactions, Qc-wt or Sec17 were omitted. No Sec18 was present under any condition. (**C**) RPLs bearing Ypt7:GTP and either the Qa and Qb SNAREs, or the R SNARE, were incubated with Qc-3∆ (80 nM), Sec17 or Sec17 FSMS (600 nM), and HOPS (50 nM) or PEG (2%). All soluble components were added together to the vesicles at t = 0. (**D**) Reactions were set up as in panel C, except that Sec17 was omitted from the initial reaction mix. After a 10 min pre-incubation at 27°C, Sec17 (wt or the FSMS loop mutant) was added at t = 0. The final reagent concentrations were the same as in panel C. For panels A-D, points denote mean plus or minus s.e.m. of 2 (**A,B**) or 6 (**B,C**) independent experiments. Lines show nonlinear best-fits of a second-order kinetic model.](elife-27396-fig10){#fig10}

How can Sec17 inhibition of fusion in the absence of HOPS be reconciled with Sec17 augmentation of fusion in the presence of HOPS? Our staging experiments with vacuoles ([Figure 8](#fig8){ref-type="fig"}) implied that HOPS and its SM subunit might be dispensable once partially zipped trans-SNARE complexes have formed. In a working model, the divergent activities of Sec17 are separated by the onset of trans-SNARE complex zippering. We therefore tested whether Sec17 can trigger fusion by stalled Qc-∆3 trans-complexes established in the complete absence of HOPS. In reactions where the Qc-∆3 and Sec17 were added together at the beginning of the reaction ([Figure 10C](#fig10){ref-type="fig"}), Sec17 stimulated Qc-3∆-driven fusion in the presence of HOPS, and far less efficiently without HOPS. The loop mutant Sec17-FSMS was unable to stimulate fusion, demonstrating that neither PEG nor HOPS bypasses the Sec17 requirement in Qc-3∆ fusion reactions.

To test Sec17 activity after trans-SNARE complexes had assembled, staged reactions were initiated with Qc-3∆ in the presence of either PEG or HOPS, but without Sec17. The reactions were incubated for 10 min to allow trans-SNARE complexes to pre-assemble ([Figure 10D](#fig10){ref-type="fig"}). Sec17 was then added to trigger fusion. Remarkably, Sec17-triggered fusion by pre-formed Qc-3∆ complexes in the PEG reactions just as efficiently as in the HOPS reactions. We conclude that HOPS not only accelerates tethering and productive trans-SNARE zippering, but also allows these processes to occur in the presence of otherwise-inhibitory Sec17. Once a partially zipped trans*-*SNARE complex has assembled, however, HOPS (and its SM subunit Vps33) are dispensable. Sec17 therefore can augment the fusion activity of a trans-SNARE complex in the total absence of an SM or other tethering factors. Indeed, when bound to the partially zipped trans*-*complex, it is likely that the SM sterically impedes C-terminal zippering, and that the SM must dissociate before fusion can initiate ([@bib5]; [@bib36]). As would be predicted if a rate-limiting SM dissociation step is bypassed in the absence of the SM, Sec17 triggered fusion with \~5 fold faster kinetics in PEG-containing reactions where HOPS/Vps33 was absent ([Figure 10D](#fig10){ref-type="fig"}).

Discussion {#s3}
==========

Increasing evidence shows that Sec17 operates not only downstream of fusion to recruit Sec18 but also upstream, during docking and trans-SNARE complex zippering. First, Sec17 physically associates with stalled trans-SNARE complexes ([@bib48]; [@bib77]; [@bib84]). Second, Sec17 can inhibit SNARE-mediated fusion by acting either prior to SNARE zippering, or, apparently, after the onset of zippering ([@bib48]; [@bib74]). Third, Sec17 can trigger fusion by interacting with partially-zipped SNARE complexes (this study; [@bib59]; [@bib64]; [@bib84]). Fourth, Sec17 and Sec18 together can disassemble stalled trans*-*SNARE complexes ([@bib56]; [@bib77]). Fifth, Sec17 and SM proteins can simultaneously and cooperatively bind quaternary SNARE bundles, with the bound SM directly opposing Sec18-mediated SNARE disassembly ([@bib34]).

Landmark structures of mammalian SNARE-α-SNAP-NSF particles ([@bib80]; [@bib81]) reveal an α-SNAP/Sec17-binding geometry optimized for interaction with both cis*-* and partially zipped trans*-*SNARE complexes ([Figure 11A](#fig11){ref-type="fig"}). One SNARE complex accommodates up to four copies of Sec17 (α-SNAP). Structures of complexes in the cis configuration reveal either two or four bound copies of α-SNAP. Membrane bilayers bridged by the metastable 'half-zipped' trans*-*SNARE complex should be 8--10 nm apart ([@bib32]; [@bib43]; [@bib85]). The membrane-proximal end of the wedge-shaped Sec17-SNARE complex is \~6 nm in diameter ([Figure 11A](#fig11){ref-type="fig"}). Membrane penetration by the N-terminal hydrophobic loop of Sec17 increases Sec17 affinity for membrane-bound SNARE complexes. ([@bib64]; [@bib84]). The loop is relatively disordered in Sec17 crystals, and likely in solution as well ([@bib54]). The flexibility of the Sec17 loop presumably allows it to touch the nearest membrane when bound to either cis*-* or trans-SNARE complexes. When two or more Sec17 molecules are on a SNARE complex, between each pair of Sec17 membrane-association loops, there is an open portal ([@bib80]). These portals ([Figure 11A](#fig11){ref-type="fig"}) would allow SNARE residues spanning the partially-zipped helical bundle and the transmembrane anchors to pass cleanly between pairs of adjacent Sec17 subunits.

![Working model.\
(**A and B**) Sec17/α-SNAP on quaternary SNARE complex (renderings based on PDB 3J96; ([@bib80]). In B, note the tapered overall shape of the SNARE-Sec17 complex, which forms a roughly triangular structure that could fit between two docked membranes bearing partially zipped SNARE complexes. The hydrophobic loop is magenta. The yellow ellipse shows one of four portals between adjacent Sec17 molecules, through which unstructured SNARE juxta-membrane regions could pass when SNAREs are complexed in the trans configuration. In C, one of four Sec17 molecules is omitted to reveal the Qc packing layers. The portal openings begin at approximately layer +6. Sec17 partially contacts the SNAREs to layer +7 or +8. (**C**) Interplay of Sec17 and SM-tethering complex on the forward fusion pathway. The early inhibitory function of Sec17 is likely to involve sequestration of SNAREs or SNARE complexes prior to the onset of trans-SNARE interactions. This early inhibition is suppressed by the SM (in our experiments, HOPS-Vps33). The late, stimulatory function of Sec17 can occur in either the absence or presence of HOPS/Vps33. When HOPS-Vps33 is present, Vps33 (SM) ejection from the SNARE complex is a prerequisite for completion of C-terminal SNARE zippering and fusion.](elife-27396-fig11){#fig11}

How does Sec17 promote fusion? Experiments with both vacuoles ([@bib59]) and RPLs (AJM, unpublished results) indicate that in Qc-∆ reactions, Sec17 addition triggers initiation of lipid mixing rather than the resolution of pre-formed hemifusion intermediates. Moreover, oligomerization of Sec17 on the SNARE complex is probably needed for augmentation of fusion. This suggestion is supported by two observations. First, Sec17 rescue of stalled Qc-∆ complexes is highly cooperative, with an apparent Hill coefficient ≥4 for Sec17 ([@bib59]). Second, rigor-locked, ATPγS-bound Sec18 further enhances the ability of Sec17 to promote SNARE-mediated fusion ([@bib64]), likely by securing multiple copies of Sec17 on the SNARE complex.

Sec17 oligomers could increase SNARE-mediated fusion through any of several mechanisms. First, Sec17 could stabilize the C-terminal domain of the partially zipped SNARE complex in its folded state. Evidence for this force-clamp mechanism has grown considerably since it was originally proposed ([@bib59]). As shown in recent cryo-EM structures ([Figure 11B](#fig11){ref-type="fig"}), α-SNAP (mammalian Sec17) contacts the Qc up to layer +5 or +6 ([@bib80]). Moreover, in force spectroscopy experiments, α-SNAP binding increases the mechanical energy derived from C-terminal zippering by \~4 k~B~T, through conformational capture of thermally fluctuating, C-terminally zipped complexes ([@bib37]). In other words, Sec17 operates as a component of a SNARE-based Brownian ratchet ([@bib50]).

In a second mechanism, bulky residues on the Sec17 hydrophobic loop might drive into the membrane as a 'wedge,' increasing membrane bending energy at the incipient fusion site ([@bib61]). There is mixed evidence in support of this mechanism. In experiments with RPLs, Sec17 fused to a SNARE transmembrane domain stimulated fusion. The membrane-tethered form of Sec17-FSMS stimulated fusion with Qc-wt but not with Qc-3∆ ([@bib64]). A limitation of these experiments is that only a single concentration of the membrane-anchored forms of Sec17 was tested. In the present study, we tested the wedge model using a different approach. If hydrophobic residues in the Sec17 loop locally expand the area of the outer bilayer leaflet, we might predict that the two aromatic residues in the Sec17 loop should be of special importance. However, these residues seem to be more important for Sec17 membrane affinity than for augmentation of fusion per se, as at higher concentrations, a mutant lacking aromatic residues in the loop still allowed Qc-3∆ to drive substantial fusion ([Figure 5](#fig5){ref-type="fig"}). Taken together, our findings here and in [@bib64] suggest that the Sec17 hydrophobic loop increases Sec17 affinity, but that a 'wedge' function may not be not strictly required for Sec17 augmentation of fusion.

In a third possible mechanism, the SM (HOPS/Vps33) is displaced when Sec17 is added to reactions with partially-zipped trans-complexes. As discussed above it is likely that SM displacement is essential for (and perhaps normally driven by) the completion of C-terminal zippering ([@bib5]; [@bib37]). We previously demonstrated that three Sec17 molecules and one SM (Vps33 or Sly1) can bind to a single SNARE complex ([@bib34]). On the partially zipped trans-complex, a fourth Sec17 molecule might competitively displace the SM ([@bib14]), facilitating the completion of SNARE zippering. However, while Sec17 may augment fusion *in part* by promoting SM ejection, we found ([Figure 10](#fig10){ref-type="fig"}) that Sec17 can stimulate fusion in the complete absence of an SM (Vps33), and indeed, that Sec17-triggered fusion occurs with faster kinetics when HOPS/Vps33 is absent ([Figure 10B](#fig10){ref-type="fig"}). An important challenge is to delineate the precise order of events that leads to SM ejection.

Our experiments here and in [@bib64] further reveal that Sec17 residue K159 contributes to Sec17 augmentation of fusion. In α-SNAP, the homologous Lys residue interacts with the SNARE complex ionic 0 layer and contributes to disassembly of cis-SNARE complexes ([@bib38]; [@bib80]). However, the K159E mutation had no detectable effect on the inhibitory function of Sec17, and Sec17-K159E is sufficient to support cellular viability ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). Intriguingly, while K159 is highly conserved among Sec17, α-SNAP, and β-SNAP orthologs, the same position is K-to-E charge-reversed in γ-SNAP ([@bib9]). This raises the intriguing possibility that the pro-fusion activity of the Sec17/α-SNAP sub-family is not shared by γ-SNAP. We speculate that γ-SNAP is expressed in cellular contexts where regulated exocytosis occurs, and where expression of α- or β-SNAP alone might increase the frequency of aberrant spontaneous exocytosis events.

Loss of SM function in vivo usually causes an absolute fusion defect. Hence, SMs have been considered to be part of the core SNARE fusion machinery ([@bib12]; [@bib69]). However, the mechanisms through which SMs promote fusion have been controversial. It is clear that some SMs stimulate SNARE-mediated fusion in vitro by several-fold in the absence of Sec17 and Sec18, but this activity is probably not sufficient to account for the all-or-nothing SM requirements consistently observed in vivo. Moreover, not all basal SNARE-mediated fusion reactions that might be predicted to be stimulated by a given SM are actually stimulated, when tested in minimal fusion systems ([@bib18]). One explanation for this is a requirement for molecular crowding, supported by experiments with synthetic crowding agents ([@bib18]; [@bib78]). In the presence of Sec17 and Sec18, however, SM activity becomes indispensable for fusion, both in vitro in the absence of crowding agents ([@bib35]; [@bib42]) and in vivo ([@bib23]; [@bib34]). Our experiments and others indicate that in the absence of the SM, Sec17 can stimulate fusion once trans-SNARE complexes are partially zippered, but that prior to trans-SNARE assembly, Sec17 (alone or in combination with Sec18) is inhibitory. In the *presence* of the SM, the early inhibitory effect of Sec17 is at least partially obscured.

Thus, it is increasingly evident that SM proteins have the properties of true enzymes. In our working model ([Figure 11C](#fig11){ref-type="fig"}), SM proteins take R- and Q-SNAREs as substrates and promote assembly of the trans-SNARE complex to its metastable half-zipped state. At the same time, the SMs prevent non-productive off-pathway reactions, including early inhibition of fusion by Sec17. In addition, the SNARE-bound SM directly impedes trans-SNARE complex disassembly by Sec18 ([@bib34]; [@bib35]; [@bib77]). The SM probably inspects the composition and shape of the incipient trans*-*SNARE complex; if the SM fails to bind, or if the SM dissociates prematurely, the inhibitory activities of Sec17 and Sec18 are unrestrained: fusion is blocked by Sec17 and the complex is then disassembled by Sec18. Tests in vivo support key predictions of this scheme. First, Sec17 overproduction rescues fusion driven by Qc-5∆ in vivo. Second, this rescue occurs only when HOPS/SM activity is augmented. These results suggest that the basal level of in vivo HOPS activity is insufficient to overcome Sec17 inhibition of early docking when Sec17 is overproduced. Third, wild-type cells show no overt defects when Sec17 is overproduced, but Sec17 overproduction causes trafficking defects and toxicity in cells with partial SM deficiency ([@bib23]; [@bib34]). The overall picture that emerges is one where SM proteins can functionally interact with SNAREs and Sec17 during docking, and SMs in turn dictate the functional outcomes of Sec17, Sec18, and SNARE interactions.

Materials and methods {#s4}
=====================

Plasmids and yeast strains {#s4-1}
--------------------------

Yeast culture and genetic manipulations were done using standard methods ([@bib1]). Strains and plasmids are listed in [Table 1](#table1){ref-type="table"}. *E. coli* expression vectors pMS108-12 were constructed as described ([@bib59]), with mutations encoded in the primers used to amplify the *VAM7* sequence. The *VAM7* knock-in plasmid pMS125 was generated by ligating two homology arms encompassing the entire *VAM7* coding sequence and surrounding regulatory sequences on either side of the *NAT1* cassette in pAG25 ([@bib20]). pMS126-9 were generated by oligo-directed mutagenesis of pMS125 to insert early stop codons. *VAM7* chromosomal knock-ins were constructed by homologous recombination in *vam7∆::KAN* yeast directed by linearized pMS125-9 followed by selection on nourseothricin. pMS120 was constructed by cloning a 2.1 kb fragment of yeast genomic DNA encompassing the entire *VAM7* coding sequence and surrounding regulatory regions (from −1000 to +1210 relative to the translational start site) into pRS426. pMS121-4 were generated by oligonucleotide-directed mutagenesis of pMS120 to introduce early stop codons. Chromosomal *YCK3* loci were ablated via homologous recombination with a PCR product derived from *yck3∆* null cells (*yck3∆::KAN).* pDN368 was generated by sequence overlap extension PCR of a *SEC17* template to introduce F21S/M22S point mutations, followed by gap repair cloning of the resulting PCR product into SacI-digested pDN526. Cell viability tests were performed using limited dilution as described ([@bib34]).
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###### Strains and plasmids used in this study

  Strain/plasmid            Description/genotype                                                                  Reference/source
  ------------------------- ------------------------------------------------------------------------------------- ---------------------
  *S. cerevisiae* strains                                                                                         
  DKY6281                   MATα *pho8∆::TRP1 leu2-3,112 ura3-52 his3-200 trp1-901 lys2-801 suc2-9*               
  BJ3505                    MATα *pep4∆::HIS3 prb1-∆1.6R ura3-52 his3-200 trp1-∆101 lys2-801 can1 gal2*           ([@bib26])
  BY4741                    MATa *his3∆one leu2∆0 met15∆0 ura3∆0*                                                 ATCC
                            BY4741 *vam7∆::KAN*                                                                   Invitrogen
  AMY1018                   BY4741 *VAM7::NAT* (Qc-wt knock-in; control wt strain)                                This study
  AMY1022                   BY4741 *vam7(1-289)::NAT* (Qc-1∆ knock-in)                                            This study
  AMY1021                   BY4741 *vam7(1-295)::NAT* (Qc-3∆ knock-in)                                            This study
  AMY1020                   BY4741 *vam7(1-302)::NAT* (Qc-5∆ knock-in)                                            This study
  AMY1019                   BY4741 *vam7(1-309)::NAT* (Qc-7∆ knock-in)                                            This study
  DNY588                    BY4741 *VAM7::NAT yck3∆::KAN*                                                         This study
  DNY591                    BY4741 *vam7(1-289)::NatR yck3∆::KAN*                                                 This study
  DNY589                    BY4741 *vam7(1-295)::NatR yck3∆::KAN*                                                 This study
  DNY590                    BY4741 *vam7(1-302)::NatR yck3∆::KAN*                                                 This study
  GOY23                     MATα *pep4∆::LEU2 prb1∆::LEU2 leu2-3,112 ura3-52 his3-200 trp1-901 lys2-801 suc2-9*   ([@bib47])
  AMY87                     BJ3505 *vam3∆*                                                                        Merz Lab collection
  RSY269                    *sec17-1*                                                                             ([@bib46])
  Yeast plasmids                                                                                                  
  pDN516                    Ap^R^ *2µ URA3*                                                                       ([@bib45])
  pDN313                    pDN516::*SEC18*                                                                       ([@bib34])
  pDN314                    pDN516::*SEC17*                                                                       ([@bib34])
  pDN315                    pDN516::*SEC17 SEC18*                                                                 ([@bib34])
  pDN365                    pDN516::*sec17-(F21S, M22S --- 'FSMS')*                                               This study
  pDN366                    pDN516::*sec17-(L291A, L292A ---'LALA')*                                              This study
  pRS416                    Ap^R^ *CEN URA3*                                                                      ([@bib63])
  pRS426                    Ap^R^ *2µ URA3*                                                                       ([@bib63])
  pMS120                    *VAM7* (pRS426; Qc-wt overproduction)                                                 This study
  pMS121                    *vam7(1-289)* (pRS426; Qc-1∆ overproduction)                                          This study
  pMS122                    *vam7(1-295)* (pRS426; Qc-3∆ overproduction)                                          This study
  pMS123                    *vam7(1-302)* (pRS426; Qc-5∆ overproduction)                                          This study
  pMS124                    *vam7(1-309)* (pRS426; Qc-7∆ overproduction)                                          This study
  pMS125                    *VAM7* (pAG25)                                                                        This study
  AMP1492                   pRS416::*SEC17*                                                                       This study
  AMP1774                   pRS416::*sec17*-K159E                                                                 
  AMP1774                   pRS416::*sec17*-K163E                                                                 This study
  AMP1774                   pRS416::*sec17*-K159E,K163E ('KEKE')                                                  This study
  *E. coli* plasmids                                                                                              
   AMP356                   pET41::*His~6~-TEV-VAM7-intein-CBD*                                                   ([@bib59])
   AMP359                   pET41::*His~6~-TEV-VAM7(1--289, 1∆)-intein-CBD*                                       ([@bib59])
   AMP1809                  pET41::*His~6~-TEV-VAM7(1--291, 2∆)-intein-CBD*                                       This study
   AMP358                   pET41::*His~6~-TEV-VAM7(1--295, 3∆)-intein-CBD*                                       ([@bib59])
   AMP1810                  pET41::*His~6~-TEV-VAM7(1--299, 4∆)-intein-CBD*                                       This study
   AMP357                   pET41::*His~6~-TEV-VAM7(1--302, 5∆)-intein-CBD*                                       ([@bib59])
   AMP1806                  pET41::*His~6~-TEV-VAM7(1--302, AR-5∆)-intein-CBD*                                    This study
   AMP1807                  pET41::*His~6~-TEV-VAM7(1--302, RA-5∆)-intein-CBD*                                    This study
   AMP1808                  pET41::*His~6~-TEV-VAM7(1--302, AA-5∆)-intein-CBD*                                    This study
   AMP360                   pET41::*His~6~-TEV-VAM7(1--309, 7∆)-intein-CBD*                                       ([@bib59])
   AMP1547                  pTYB12::intein-CBD-*SEC17*                                                            ([@bib59])
   AMP1547                  pTYB12::intein-CBD-*SEC17* (F21R, M22S, L24S, F25R)                                   This study
   AMP1548                  pTYB12::intein-CBD-*SEC17* (F21R, F25R)                                               This study
   AMP1549                  pTYB12::intein-CBD-*SEC17* (∆21--25)                                                  This study
   AMP1550                  pTYB12::intein-CBD-*SEC17* (F21S, M22S --- 'FSMS')                                    This study
   AMP1551                  pTYB12::intein-CBD-*SEC17* (∆1--26)                                                   This study
   AMP1777                  pTYB12::intein-CBD-*SEC17* (K159E)                                                    This study
   AMP1778                  pTYB12::intein-CBD-*SEC17* (K163E)                                                    This study
   AMP1779                  pTYB12::intein-CBD-*SEC17* (K159E, K163E --- 'KEKE')                                  This study

Proteins and lipids {#s4-2}
-------------------

Sec17, Sec17^FM\>SS^, and Qc-SNAREs were expressed in *E. coli* and purified as described ([@bib59]). A two-tag strategy was employed. An N-terminal polyhistidine tag and a C-terminal, self-cleaving intein and chitin-binding domain tag, allowed retrieval of Qc proteins uncontaminated by N- or C-terminal cleavage products. Sec18 was expressed in *E. coli* and purified as described ([@bib39]). Full-length Vam3, Vti1 and Nyv1 were expressed in *E. coli* and purified as described ([@bib42]; [@bib84]; [@bib86]). Ypt7 and HOPS were overproduced in yeast and purified as described ([@bib82]). Cy5-strepavidin was purchased from KPL, unlabeled avidin from Thermo Scientific (Bothell, Washington, USA), and R-phycoerythrin-biotin from Life Technologies. Monoclonal antibodies against ALP (Pho8), CPY (Prc1) and PGK1 were purchased from Molecular Probes (Life Technologies, Carlsbad, California, USA). Affinity-purified antibodies against Vam3, Vam7, Nyv1, Vti1, Sec17, Sec18, and Vps33 were prepared as described ([@bib59]). Lipids were purchased from Avanti Polar Lipids (Alabaster, Alabama, USA), except for ergosterol (Sigma-Aldrich, Saint Louis, Missouri, USA) and fluorescent lipids (Life Technologies).

Microscopy {#s4-3}
----------

For fluorescent labeling of yeast vacuoles ([@bib72]), cell cultures were shaken at 30°C and grown to early logarithmic phase (OD~600~ = 0.3 to 0.6). Cells were pelleted and resuspended in synthetic media supplemented with 5 µM FM4-64 (Life Technologies), then incubated ≥20 min at 30°C. Labeled cells were rinsed once in synthetic media before resuspension in synthetic complete or dropout media and shaking at 30°C for 30 to 60 min. Cells were maintained in logarithmic growth phase (OD~600~ = 0.3 to 0.8) until observation by microscopy. Epifluorescence microscopy was performed as described ([@bib49]).

Vacuole protein sorting analysis {#s4-4}
--------------------------------

10 mL of cells were grown to OD~600~ = 1.0 in synthetic complete media lacking appropriate nutrients to maintain plasmid selection. Cells were retrieved by centrifugation, suspended in 100 µL 1 × SDS loading buffer with 100-µL glass beads, heated to 95°C for 10 min, and vortexed for 5 min to disrupt the cell wall and cell membrane. Cell extracts were separated from glass beads by centrifugation at 1000 × g, and then insoluble material was removed by centrifugation at 20,000 × g. Samples were analyzed by SDS‐PAGE and western blotting.

Immunoprecipitation {#s4-5}
-------------------

For SNARE immunoprecipitations, affinity-purified Vam3 antibodies were covalently coupled to Protein A agarose beads using dimethyl pimelimidate (DMP; Pierce) as described ([@bib22]). Logarithmic phase cultures were harvested and spheroplasted. Briefly, 20 OD~600~·mL of cells were sedimented then resuspended in 2 mL 0.1 M Tris·Cl pH 9.4, 10 mM DTT for 10 min at room temperature. Cells were sedimented and resuspended in 4 mL spheroplasting buffer (yeast nitrogen base, 2% w/v glucose, 0.05% w/v casamino acids, 1M sorbitol, 50 mM Na·HEPES pH 7.4), then incubated with lyticase (re-purified Zymolyase 20T; Sekigaku USA, Jersey City, New Jersey, USA) at 30°C for 30 min. Spheroplasts were sedimented once in spheroplasting buffer and resuspended in 2 mL ice-cold lysis buffer (20 mM Na·HEPES pH 7.4, 100 mM NaCl, 20% w/v glycerol, 2 mM EDTA, 1 µg/mL aprotinin, 1 µg/mL leupeptin, 1 µg/mL pepstatin, 0.1 mM Pefabloc-SC, 1 mM PMSF, and a protease inhibitor cocktail (Roche, Indianapolis, Indiana, USA)), and lysed by \~30 strokes with an ice-cold dounce homogenizer. Cell lysates were supplemented with 1% (v/v) Anapoe X-100 (Anatrace, Moumee, Ohio, USA) and nutated at 4°C for 15 min. Insoluble debris was removed by centrifugation at 20,000 × g for 15 min at 4°C. Clarified lysate was mixed with anti-Vam3-protein A beads and nutated for 30 min at 4°C. Beads were recovered by low-speed centrifugation and rinsed four times in lysis buffer containing 0.5% (v/v) Anapoe X-100. Bound proteins were eluted by boiling in SDS-PAGE sample buffer ([@bib29]). Unbound proteins remaining in the cell lysates were precipitated by addition of 1/10 vol. 0.15% deoxycholate and 1/10 vol of 100% TCA. The precipitates rinsed twice in acetone and resuspended in sample buffer (40 µL per OD~600~ × mL equivalent). Samples were separated by SDS-PAGE, electroblotted to nitrocellulose, probed with primary antibodies as indicated in the figures and secondary antibodies as recommended by the manufacturer (LiCor), and analyzed on a LiCor Odyssey imaging system. For Vps33-GFP, anti-GFP immunoprecipitations were conducted as described in [@bib14], with slight modifications, using vacuoles purified from the strain BJ2168‐Vps33‐GFP (*MATα leu2‐3, 112 trp1‐∆101 ura3‐52 prb1‐1122 pep4‐three pcr1‐407 VPS33‐GFP* (*TRP1*). Extracts were clarified at 20,000 × g for 20 min at 4°C. Extracts were incubated for 3 hr with affinity resins and eluted by boiling in SDS sample buffer. The fusion capacity of the vacuole preparations used for the immunoprecipitations was verified in parallel cell-free fusion reactions containing both BJ2168‐Vps33‐GFP reporter and DKY6281 acceptor vacuoles.

In vitro fusion assays {#s4-6}
----------------------

Vacuole fusion assays were performed as described previously ([@bib59]). Dose-activity curves were fitted with the Hill single-site model with adjustable slope, using the nonlinear least-squares method (GraphPad Prism). Dose-inhibition curves for Sec17 were fit with the same model but with the slopes locked to unity, after determining that an adjustable slope parameter did not improve the fits. RPLs were formed by dialysis from β-octylglucoside proteolipid mixed micelles as in [@bib84], in the configurations shown in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, and purified by equilibrium floatation. A defined lipid composition similar to that of the yeast vacuole was employed (vacuolar membrane lipids, (VML; [@bib83]). The protein:lipid ratios were 1:1000 for Qa, Qb, and R SNAREs, and 1:2000 for Ypt7. The RPL fusion assays were set up as described ([@bib84]) but that bovine serum albumin was omitted from all RPL reactions except those shown in [Figure 10C,D](#fig10){ref-type="fig"}. 100% fusion was defined as complete association of the FRET probes encapsulated within the two vesicle populations, as determined in control reactions. 0% fusion was defined by control reactions with no added Qc-SNARE. Reaction kinetics were fitted with a second-order association model by the nonlinear least squares method using GraphPad Prism.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Sec17 (α-SNAP) and an SM-tethering complex control the outcome of SNARE zippering in vitro and in vivo\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors and the evaluation has been overseen by Randy Schekman as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Josep Rizo (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The reviewers have discussed the reviews with one another and the Reviewing Editor. As you will see from the detailed review below, they have identified several issues that are sufficiently serious to preclude publication of the current manuscript in *eLife*. Nevertheless, the editor and the reviewers feel that it might be possible, and also worthwhile, for you to address these issues in a revised manuscript. We emphasize, however, that the reservations are serious ones, and that a positive decision concerning publication can only be made if the revised manuscript satisfactorily addresses these concerns.

Please let *eLife* staff know if you feel that you can address these issues within two months, and plan to submit a revised manuscript. Alternatively, if you feel that this may not be realistic, please let us know that as well.

Summary: This manuscript is related to Wickner et al., which is currently under revision at *eLife*. There are two substantial areas where this paper complements Wickner\'s paper: (1) testing of different truncation mutants of Vam7 with native vacuoles. Similar to what is reported in Wickner\'s paper using synthetic proteoliposomes, deletion of three layers (Qc-3∆) causes a defect. If an additional layer is truncated (Qc-2∆), Sec17 does not rescue, but if fewer layers are omitted (Qc-4∆), Sec17 rescues the effect of the truncation mutants similar to what is reported in Wickner\'s paper. (2) Sec17 has both inhibitory and fusion-promoting effects depending if it is acting before or after HOPS is included.

Essential revisions:

1\) As the reviewers also suggested for the related paper, in the context of Figures 3 and 8, it would be interesting to also probe the interactions found by Zhao et al., (2015) that affect the interaction between aSNAP and the SNARE complex, in particular mutations that interact with SNARE residues near the ionic layer and that disrupt disassembly function (Figure 6 in Zhao et al., 2015). Such an experiment would support the proposed notion that it is the interaction between Sec17 and the SNARE complex that compensates for the deletion of the C-terminal residues of Vam7 (Figure 3), and if the inhibitory activity of Sec17 ([Figure 8](#fig8){ref-type="fig"}) also depends on this interaction.

2\) Throughout the manuscript it is suggested that Sec17 promotes fusion. However, an alternative explanation could be that this is an indirect effect caused by the interaction of Sec17 with the SNARE complex, i.e. Sec17 would make the SNARE complex more fusogenic, similar to the role of HOPS as proposed by Zick & Wickner, (2014), and see also Baker et al., 2015. Another possibility would be that the hydrophobic loops play a role in recruitment of Sec17 to the membrane. Finally, the loops could perturb the membrane, and indeed play a more direct role in fusion. It would be desirable to discuss such an alternative explanation and perhaps tone down the wording related \"fusion\" in several places in the manuscript.

3\) The manuscript is poorly written, not in terms of grammar but with regard to logical flow and inclusion of sufficient explanations of the experiments that were performed. Often the figure legends do not contain enough details to understand what is shown and just give a conclusion. The experimental section also needs a lot more detail.

4\) The related paper by Wickner et al., is only briefly mentioned in a few places. Considering the partial overlap and complementarity between these papers, the key findings of the Wickner et al., paper should be introduced and summarized in the Introduction and then discussed again in the conclusions.

5\) One of the key results is the synergy observed between Sec17 and Sec18 in Figure 4. However, this synergy is pretty much ignored in the main conclusions of the paper, including the title, the abstract and the discussion. This is particularly worrisome because the paper is co-submitted with another paper that also makes a strong point on this synergy. And most problematic of all is the fact that it is not clear if the experiments were performed in the presence of Mg-ATP. This is critical, because the results would be very interesting if Mg-ATP were not present, as they would suggest roles in fusion for both Sec17 and Sec18. However, if Mg-ATP were present, the results are expected because Sec18 and Sec17 can synergize in disassembling unproductive t-SNARE complexes (which has been very well documented by the Wickner lab).

6\) The title and several parts of the manuscript suggest that the authors are bringing key insights into the function of SM proteins and why are they so essential. However, it is not so clear what are the new insights and the discussion is particularly confusing in this respect. The data of Figure 8 show some very interesting differences in the need for HOPS depending on the way the experiments are staged, but the implications of the results are not clearly explained-discussed. Note also that this aspect of the paper was limited to including only the Qc-3∆ complex. Data obtained with other Qc-∆ complexes as in Figure 4 would strengthen the story and the potential conclusions that can be drawn.

7\) Discussion section. Please note that Zhao et al., 2015 also reported a 20S complex with only two aSNAPs bound (Figure 7 in that paper, involving VAMP-7). The experiments reported here suggest that if there were only two Sec17 molecules bound to the vacuolar SNARE complex, then they should interaction with the Qc \"face\" of the SNARE complex in order to stabilize the truncated cis-SNARE complex. This would allow one SM molecule bind to the face that is not occupied by Sec17 molecules. This possibility should be discussed.

8\) Figure 6B shows a significant decrease in the rate of membrane fusion when the wild-type Sec17 is present in a high concentration, which is not seen in Figure 4. Is the decrease caused by inhibition of initial SNARE zippering by Sec17?

9\) Figure 7A is difficult to understand and does not well compare to Figure 7B. Does Figure 7A indicate that Rab and SM are not important to nucleate SNARE zippering?

10\) Please clarify the statement in the Introduction: \"Reconstitution experiments suggested that the SM requirement is fully realized only in the presence of Sec17 and Sec18\" and similar arguments in the Introduction. In the absence of Sec17 and Sec18, Munc18-1 is shown to enhance the rate of SNARE-mediated membrane fusion by \~10 fold (Yu et al., 2015; Shen 2007), which is as much as in the presence of Sec17 and Sec18.

11\) In subsection "Sec17 interacts with partially-zipped SNAREs to control fusion", it is stated that \"We further propose that this state corresponds to metastable, partially-zipped SNARE conformations observed in force spectroscopy studies (Liu et al., 2006; Min et al., 2013; Zorman et al., 2014). In the \"half-zipped\" state, the neuronal t/Q-SNARE complex is structured to layer +4 (Ma et al., 2016), a result in precise agreement with the present experiments.\" The citations here are not so accurate. Liu et al., did not observe a half-zippered state as in other references cited here. The work of Ma et al., 2016, did not reveal any structure partially zippered to +4. Another work of Ma et al., 2015 revealed two partially-zippered states, one between layers -1 and 0 and the other between layers 2 and 3, but not layer +4, because the VAMP2 mutation at this layer decreased zippering of the C-terminal domain, but not other domains.

12\) Figure 8D-E: The observation that SM proteins attenuate SNARE CTD zippering was previously reported for Munc18-1 in Ma et al., 2015. This finding is counter-intuitive, but is also consistent with the template model proposed by Baker et al.

13\) Discussion section: \"Fifth, Sec17 and SM proteins can simultaneously and cooperatively bind quaternary SNARE bundles, with the bound SM opposing Sec18-mediated SNARE disassembly\". It may be confusing to emphasize this point, because the authors stated earlier that SM proteins should be displaced for SNAREs to fully zipper. It is understandable that SM proteins protect the functionally important partially-zippered SNARE complex from pre-mature disassembly by Sec17 and Sec18. What\'s the biological function for SM proteins to protect the assembled helix bundle?

14\) Discussion section: \"First, Sec17 could stabilize the partially-zipped SNARE complex\". This sentence may be confusing. Stabilizing the partially-zippered SNARE complex would either promote initial SNARE zippering (relative to unzipped state) or hinder CTD zippering (relative to the folded four-helix bundle state), which contradicts the model shown in Figure 9. It seems that Sec17 stabilizes the folded four-helix bundle state.

15). In subsection "HOPS selects the outcome of Sec17--SNARE interactions", the authors write \'Sec17 triggered fusion by pre-formed Qc-3∆ complexes in PEG reactions just as efficiently as in the HOPS reactions\', but the data in Figure 8D suggest that the HOPS reaction is actually quite slower. This could be an important result. What does it mean?

16\) When discussing the observation that Sec17 can inhibit fusion, the authors should consider the possibility that such inhibition arises because of binding of Sec17 to non-productive t-SNARE complexes, thus stabilizing these complexes and preventing SNARE complex assembly.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Sec17 (α-SNAP) and an SM-tethering complex regulate the outcome of SNARE zippering *in vitro* and *in vivo* for further consideration at *eLife*. Your revised article has been favorably evaluated by Randy Schekman (Senior editor), and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

The last sentence of the abstract and also the last one of the introduction suggest that they authors are uncovering the reason for the essential nature of SM proteins. However, the major concepts underlying this essential nature (the orchestration of SNARE complex assembly while protecting against disassembly by Sec18-Sec17) were already shown a long time ago by the Wickner lab. The authors do add another layer by providing evidence that HOPS prevents the inhibitory function of Sec17, which is interesting, but cannot be considered \'the observation\' that makes SM proteins essential. In this context, the importance of Wickner\'s work is also ignored in the third paragraph of the introduction. The authors should rephrase all these parts of the manuscript accordingly.

In the Results section and particularly in the Discussion section, the authors argue against the idea that the N-terminal hydrophobic loop of Sec17 acts as a wedge to induce membrane fusion, but the argument is quite weak because it is based on the data acquired with one mutant (with the RSKSR sequence in the loop) that needs to be added at high concentrations to support fusion.

The authors previously published that Sec17 enhances SM protein binding to the SNARE complex, while now they propose that Sec17 dissociates the SM protein. This apparent contradiction was previously pointed out and was not properly addressed in the rebuttal letter or in the manuscript.

There is no legend for Figures 7D, E.

The title of Figure 9 is too strong as the conclusion is not really demonstrated by the data.

The error bars in Figure 4 are plotted in a weird asymmetrical way as if the data are poorly fit. I would suggest a symmetric way to plot the error (mean with + and -- std or sem).
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Author response

> This manuscript is related to Wickner et al., which is currently under revision at eLife. There are two substantial areas where this paper complements Wickner\'s paper: (1) testing of different truncation mutants of Vam7 with native vacuoles. Similar to what is reported in Wickner\'s paper using synthetic proteoliposomes, deletion of three layers (Qc-3∆) causes a defect. If an additional layer is truncated (Qc-2∆), Sec17 does not rescue, but if fewer layers are omitted (Qc-4∆), Sec17 rescues the effect of the truncation mutants similar to what is reported in Wickner\'s paper. (2) Sec17 has both inhibitory and fusion-promoting effects depending if it is acting before or after HOPS is included.

We thank the Referees for many useful and constructive comments.

We have made major revisions throughout the manuscript. The sections most heavily revised are noted by vertical lines on the left and right sides of the text, or by underlining. We have also added a lot of new data: almost all of [Figure 5](#fig5){ref-type="fig"}, all of [Figure 6](#fig6){ref-type="fig"}, all of [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}, and [Figure 9A](#fig9){ref-type="fig"}.

> Essential revisions:
>
> 1\) As the reviewers also suggested for the related paper, in the context of Figures 3 and 8, it would be interesting to also probe the interactions found by Zhao et al., (2015) that affect the interaction between aSNAP and the SNARE complex, in particular mutations that interact with SNARE residues near the ionic layer and that disrupt disassembly function (Figure 6 in Zhao et al., 2015). Such an experiment would support the proposed notion that it is the interaction between Sec17 and the SNARE complex that compensates for the deletion of the C-terminal residues of Vam7 (Figure 3), and if the inhibitory activity of Sec17 (Figure 8) also depends on this interaction.

This was a great idea. We constructed and purified three Sec17 mutants: K159E, K163E, and a mutant containing both substitutions ("KEKE"). RPL fusion and binding experiments with the Sec17-KEKE mutant are reported in Song et al. Vacuole fusion experiments and in vivo functional tests are reported for all three mutants in this study. In addition, we now characterize four new mutations in the Sec17 hydrophobic loop, in vacuole fusion assays (new [Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}). The ionic layer interaction mutants and the loop mutants have dramatically divergent properties.

In new experiments testing the ability of the mutants to rescue fusion with partially-zipped (Qc-3∆) SNARE complexes (new [Figure 5A](#fig5){ref-type="fig"}), the Sec17 K159E mutant exhibits a \~1-log rightward shift in the Sec17 dose-response curve, as well as a decreased total fusion response. Sec17 K163E, on the adjacent α-helix, acts like the wild type, while the KEKE double mutant acts like the K159E single mutant -- affirming the importance of the zero layer-interacting residue K159. In addition, all five hydrophobic loop mutants (new [Figure 5B](#fig5){ref-type="fig"}) are severely compromised in their ability to trigger fusion with Qc-3∆ SNARE complexes. We conclude that both the Sec17 hydrophobic loop and Sec17 interaction with the SNARE complex near layer 0 are important for Sec17 augmentation of fusion.

In a second set of additional experiments (new [Figure 6](#fig6){ref-type="fig"}) we tested the inhibitory effects of the substitutions. The charge reversal mutations at positions 159 and 163 had no detectable effect on the dose-response of inhibition. In dramatic contrast, mutants in the N-terminal hydrophobic loop were inhibitory only at concentrations 40-200 times higher than the wild type. We conclude that Sec17 position K159 is important for maximal SNARE disassembly and for efficient rescue of partially zipped (Qc-3∆) SNARE complexes, but that K159 has no obvious role in the inhibition of fusion by Sec17. This in turn implies that membrane interaction, but not SNARE ionic layer interaction, is important for Sec17-mediated inhibition of fusion -- just as the referee seems to have surmised. These new experiments have been integrated into the manuscript.

> 2\) Throughout the manuscript it is suggested that Sec17 promotes fusion. However, an alternative explanation could be that this is an indirect effect caused by the interaction of Sec17 with the SNARE complex, i.e., Sec17 would make the SNARE complex more fusogenic, similar to the role of HOPS as proposed by Zick & Wickner, (2014), and see also Baker et al., 2015. Another possibility would be that the hydrophobic loops play a role in recruitment of Sec17 to the membrane. Finally, the loops could perturb the membrane, and indeed play a more direct role in fusion. It would be desirable to discuss such an alternative explanation and perhaps tone down the wording related \"fusion\" in several places in the manuscript.

We agree with the referees' interpretation here, and indeed we explicitly proposed possible alternative mechanisms similar to those suggested by the referee in our original Discussion. Here is the relevant text:

[How does Sec17 promote lipid mixing? First]{.ul}, Sec17 could stabilize the partially-zipped SNARE complex. α-SNAP (mammalian Sec17) Sec17 contacts the Qc up to layer +5 or +6 (Figure 9C; Zhao et al., 2015), and single molecule experiments with partially-zipped SNARE complexes reveal that α-SNAP stabilizes C-terminal zippering by \~4 k~B~T, through "conformational capture" of thermally fluctuating, partially-zipped complexes. In other words Sec17 may operate as part of a SNARE-based Brownian ratchet (Peskin et al., 1993). [Second]{.ul}, Sec17 bound to the trans-SNARE complex may operate as a wedge that increases local membrane bending energy at the fusion site ([Figure 9B](#fig9){ref-type="fig"}). [Third]{.ul}, the hydrophobic residues in Sec17 may locally perturb the outer bilayer leaflet, as proposed for synaptotagmin in Ca^2+^-triggering of synchronous neurotransmitter release. Indeed, Sec17 and synaptotagmin compete for binding to SNARE complexes (Sollner et al., 1993), suggesting that Sec17 and synaptotagmin may be alternative factors that execute analogous triggering functions. [Fourth]{.ul}, we have previously shown that three Sec17 molecules and one SM can bind to a single SNARE complex (Lobingier et al., 2014). A fourth Sec17 molecule might competitively displace the SM (Collins et al., 2005), facilitating the completion of SNARE zippering. Consistent with this idea, Sec17 rescue of stalled Qc-∆ complexes is highly cooperative, with an apparent Hill coefficient ≥4 (Schwartz and Merz, 2009). The idea that Sec17 oligomerization is needed for Sec17's fusogenic function is further supported by the finding that rigor-locked, ATPγS-bound Sec18 augments the fusogenic activity of Sec17 (Wickner et al.). \[Emphasis added\]

We did not intend to assert that Sec17 directly catalyzes fusion but rather that in the presence of Sec17, SNARE-mediated fusion is stimulated or augmented. In the revised manuscript we take greater care to be precise on this point, and we've avoided using the word "fusogenic" when referring to Sec17.

> 3\) The manuscript is poorly written, not in terms of grammar but with regard to logical flow and inclusion of sufficient explanations of the experiments that were performed. Often the figure legends do not contain enough details to understand what is shown and just give a conclusion. The experimental section also needs a lot more detail.

We apologize for the overly telegraphic style. We have revised the Results section, Materials and methods section and Legends to add (or emphasize) critical experimental details. We have also added new experiments (new [Figures 5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}, [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}, [9A](#fig9){ref-type="fig"}) and promoted figure panels from the supplemental section to the main body ([Figures 5B](#fig5){ref-type="fig"}, [7D, 7E](#fig7){ref-type="fig"}), in order to improve the stepwise logic of the manuscript.

> 4\) The related paper by Wickner et al., is only briefly mentioned in a few places. Considering the partial overlap and complementarity between these papers, the key findings of the Wickner et al., paper should be introduced and summarized in the Introduction and then discussed again in the conclusions.

In the previous submission, the manuscript by Wickner et al., (now Song et al., 2017) was referenced no fewer than ten separate times in the Introduction, Results section and Discussion section. With the Song et al., paper now revised and published, we present further comparisons.

> 5\) One of the key results is the synergy observed between Sec17 and Sec18 in Figure 4. However, this synergy is pretty much ignored in the main conclusions of the paper, including the title, the abstract and the discussion. This is particularly worrisome because the paper is co-submitted with another paper that also makes a strong point on this synergy. And most problematic of all is the fact that it is not clear if the experiments were performed in the presence of Mg-ATP. This is critical, because the results would be very interesting if Mg-ATP were not present, as they would suggest roles in fusion for both Sec17 and Sec18. However, if Mg-ATP were present, the results are expected because Sec18 and Sec17 can synergize in disassembling unproductive t-SNARE complexes (which has been very well documented by the Wickner lab).

We did not dwell on the synergy with Sec18 because an exploration of that synergy is a central focus of Song et al., (2017). All treatments in our were indeed done in the presence of 1 mM Mg•ATP (not ATPγS); that was indicated directly in earlier drafts and accidentally omitted. We apologize for the oversight. We agree with the referee's interpretation that one function of Sec18 is to recycle unproductive SNARE complexes so that they get additional chances to catalyze fusion. Indeed, a mutant breaking the Sec17-Sec18 interaction (*SEC17-LALA*) is one of the few directed mutations in Sec17 that renders cells inviable (new [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). When overproduced, Sec17-LALA protein is dominant-negative (our unpublished results). This implies that Sec18-mediated SNARE disassembly is, as most would expect, the core and essential function of Sec17. The key point here, however, is that even in the absence of Sec18 or Sec18 activity, Sec17 augments the fusion capacity of SNARE truncation mutants or (as we have shown in Zick et al., 2015 and Song et al., 2017) full-length SNARES. We reiterate that we first reported that Sec17 can augment fusion without Sec18 in Schwartz and Merz (JCB 2009). In that paper we demonstrated Sec17 stimulation of fusion with Qc-3∆ and native vacuoles in the presence of inhibitory anti-Sec18 antibodies and in the absence of ATP or ATPγS.

> 6\) The title and several parts of the manuscript suggest that the authors are bringing key insights into the function of SM proteins and why are they so essential. However, it is not so clear what are the new insights and the discussion is particularly confusing in this respect.

The core of our argument is that Sec17, in addition to its canonical functions in post-fusion SNARE disassembly, has *both* inhibitory and stimulatory effects on the forward docking and fusion pathway. We show that the effects of Sec17 are different before and after trans-SNARE complex assembly to a partially-zipped intermediate, and we demonstrate that one function of the SM is to help its cognate SNAREs "choose" which modes of Sec17 action will predominate: specifically, the SM allows the reaction to bypass the early inhibitory action of Sec17. For these reasons, Sec17 comes before the SM in the paper's title.

It's also critical to note that nearly all published data on the roles of Sec17 in docking and fusion has been derived from in vitro systems. When this paper was submitted, there was only one other study we're aware of (Lobingier et al., 2014) that begins to tie together the multiple functions of Sec17, and the interplay between Sec17 and SMs, in parallel experiments conducted both in vitro and in vivo. (Another, very interesting in vivo paper on Munc18, NSF, and priming was published about a week ago; He ... Verhage, 2017). We want to know how the biochemistry plays out in life. This manuscript and our previous studies represent steps toward that broader, longer-term goal. We have revised our discussion to clarify what we know about SM function in vivo vs. in vitro.

> The data of Figure 8 show some very interesting differences in the need for HOPS depending on the way the experiments are staged, but the implications of the results are not clearly explained-discussed. Note also that this aspect of the paper was limited to including only the Qc-3∆ complex. Data obtained with other Qc-∆ complexes as in Figure 4 would strengthen the story and the potential conclusions that can be drawn.

Because the Qc-4∆ and Qc-3∆ complexes exhibit indistinguishable behavior in our assays, it wasn't clear what hypotheses would be tested by this comparison. However, we analyzed a new series of Sec17 mutations in both the SNARE 0-layer binding region (3 mutants) and in the Sec17 apolar loop (5 mutants). The resulting new data are shown in [Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"} of the revised manuscript, and as summarized in the Results section and in our reply to Query \#1, the results were highly informative. We've made every effort to more clearly spell out the implications of the experiment in the former Figure 8 (now [Figure 10](#fig10){ref-type="fig"}), and we've added a key experiment in [Figure 9A](#fig9){ref-type="fig"}, showing ejection of Vps33/HOPS from the SNAREs when Sec17 is added to trigger fusion.

> 7\) Discussion section. Please note that Zhao et al., 2015 also reported a 20S complex with only two aSNAPs bound (Figure 7 in that paper, involving VAMP-7). The experiments reported here suggest that if there were only two Sec17 molecules bound to the vacuolar SNARE complex, then they should interaction with the Qc \"face\" of the SNARE complex in order to stabilize the truncated cis-SNARE complex. This would allow one SM molecule bind to the face that is not occupied by Sec17 molecules. This possibility should be discussed.

As we wrote in the Discussion section of the original submission (emphasis added):

Recent structures of mammalian SNARE-Sec17-Sec18 particles [(Zhao et al., 2015)]{.ul}(Zhou et al., 2015) reveal a Sec17 geometry precisely optimized for interaction with both cis- and partially-zipped trans-complexes ([Figure 9B](#fig9){ref-type="fig"}). *Up to four Sec17 molecules* bind each SNARE complex \[...\] we have previously shown that three Sec17 molecules and one SM can bind to a single SNARE complex (Lobingier et al., 2014). A fourth Sec17 molecule might competitively displace the SM (Collins et al., 2005), facilitating the completion of SNARE zippering. Consistent with this idea, Sec17 rescue of stalled Qc-∆ complexes is highly cooperative, with an apparent Hill coefficient ≥4 (Schwartz and Merz, 2009). The idea that Sec17 oligomerization is needed for Sec17's fusogenic function is further supported by the finding that rigor-locked, ATPγS-bound Sec18 augments the fusogenic activity of Sec17 (Wickner et al.,).

In other words, we think we're in agreement with the Referee on this point. We have modified the text to be sure that readers understand the point that 0-4 Sec17 molecules can bind the SNARE complex. In addition, we have now tested a key prediction of the model. In the new [Figure 9A](#fig9){ref-type="fig"} we show that HOPS/Vps33 associates with the Qc-3∆ SNARE complex in a docking reaction that depends on the Ypt7 Rab; HOPS/Vps33 then dissociates from the SNAREs when fusion is triggered by Sec17 addition.

> 8\) Figure 6B shows a significant decrease in the rate of membrane fusion when the wild-type Sec17 is present in a high concentration, which is not seen in Figure 4. Is the decrease caused by inhibition of initial SNARE zippering by Sec17?

We infer that at higher Sec17 concentrations, the reduced rescue of Qc-∆ SNARE complexes is due to inhibition at an early, pre-zippering stage -- probably cis-capture of SNAREs, as originally suggested by Wang et al., (2004). We use reaction conditions like those of Wang et al., in our newly-added evaluation of inhibition by Sec17 and its mutants ([Figure 6](#fig6){ref-type="fig"}).

Jahn's lab has proposed an alternative inhibitory mechanism of α-SNAP; in those experiments, the inhibition seems to occur after zippering has initiated (Park et al., 2014). Both the kinetic and staging data in this manuscript, and the earlier vacuole work by Wang et al., are consistent with inhibition before rather than after trans-SNARE complex formation.

In this context it may be useful to note that results with RPLs and vacuoles are broadly consistent. The two Sec17 concentrations chosen for our RPL experiments in [Figure 4](#fig4){ref-type="fig"} (100 and 600 nM) correspond to Sec17 concentrations that resulted in \~10% rescue and near-maximal Qc-3∆ or Qc-4∆ rescue, in experiments with vacuoles in vitro (see new [Figure 5](#fig5){ref-type="fig"}). In the Song et al., companion study, no dose-response curves were presented, and only a single Sec17 concentration (660 nM) was evaluated, for both WT and mutant forms of Sec17. Similarly, only a single Sec18 concentration, 334 nM, was tested in the Song et al., study.

> 9\) Figure 7A is difficult to understand and does not well compare to Figure 7B. Does Figure 7A indicate that Rab and SM are not important to nucleate SNARE zippering?

[Figure 8A](#fig8){ref-type="fig"} (formerly 7A), the new [Figure 9A](#fig9){ref-type="fig"}, and published results (e.g. Ungermann et al., 1998; Collins and Wickner, 2007; Schwartz and Merz, 2009) all indicate that the Rab and SM are critical for nucleation of SNARE zippering with either full-length Qc (Vam7) or Qc-∆ proteins on native vacuoles. We now emphasize this point more strongly in the Results section and Discussion section.

> 10\) Please clarify the statement in the Introduction: \"Reconstitution experiments suggested that the SM requirement is fully realized only in the presence of Sec17 and Sec18\" and similar arguments in the Introduction. In the absence of Sec17 and Sec18, Munc18-1 is shown to enhance the rate of SNARE-mediated membrane fusion by \~10 fold (Yu, et al., 2015; Shen, 2007), which is as much as in the presence of Sec17 and Sec18.

In Shen et al., (2007), stimulation of the initial rate of fusion by \>5-fold was observed solely with pre-assembled SNARE complexes that incorporated a place-holder VAMP2 "cdv2" fragment, while both Furukawa and Mima, (2014), and Yu et al., (2015) reported SM stimulation \>5-fold in the presence of molecular crowding agents. We agree that these are pioneering experiments, and we now discuss them in a bit more detail. However, synthetic crowding agents might or might not replicate crowding in the native cytoplasmic environment: it is established that synthetic crowding agents can also eliminate known in vivo requirements for Rabs, for tethering factors such as HOPS, and even for the SM proteins themselves (e.g. Dennison et al., 2006; Hickey and Wickner, 2010; Zick and Wickner, 2013; this manuscript).

It is at least as clear that in the absence of an SM, Sec17 and Sec18 + Mg•ATP can completely suppress basal SNARE mediated fusion (e.g., Mima et al., 2008; Ma et al., 2013). Moreover, the combination of an SM with Sec17 and Sec18 + Mg•ATP) yields synergistic fusion over and above that seen with an SM plus SNAREs alone (ibid.; Song et al., 2017; this manuscript). This might originally have been attributed solely to the "churning" function of Sec18: cycles of assembly and disassembly giving more SNARE complexes the opportunity to trigger fusion. However, experiments in systems lacking either Mg•ATP, active Sec18, or both (Shwartz and Merz, 2009; Zick et al., 2015; Song et al.,; and this manuscript) suggest that there is more going on here than solely Sec18-catalyzed churning of SNARE complexes. Together, the data suggest models in which the SM functions not only with the SNAREs alone, but as an interaction partner of Sec17 (and perhaps of Sec18) on the forward docking and fusion pathway.

We emphasize that this interpretation not only does not exclude, but *requires, and is an elaboration on*, the increasingly well-accepted hypothesis that SMs are sensu stricto catalysts of forward trans-SNARE complex formation.

We have re-worded the section flagged by the referee to clarify these points.

> 11\) In subsection "Sec17 interacts with partially-zipped SNAREs to control fusion", it is stated that \"We further propose that this state corresponds to metastable, partially-zipped SNARE conformations observed in force spectroscopy studies (Liu et al., 2006; Min et al., 2013; Zorman et al., 2014). In the \"half-zipped\" state, the neuronal t/Q-SNARE complex is structured to layer +4 (Ma et al., 2016), a result in precise agreement with the present experiments.\" The citations here are not so accurate. Liu et al., did not observe a half-zippered state as in other references cited here. The work of Ma et al., 2016, did not reveal any structure partially zippered to +4. Another work of Ma et al., 2015 revealed two partially-zippered states, one between layers -1 and 0 and the other between layers 2 and 3, but not layer +4, because the VAMP2 mutation at this layer decreased zippering of the C-terminal domain, but not other domains.

We could and should have been more precise in our citation of the literature. We have improved the passage in question and we are grateful to the Referee for pointing out that deficiency. We agree it's arguable that Liu et al., did not observe a half-zipped state (but were attempting to give the benefit of the doubt in our citation of prior art).

Nevertheless, the original summary of the state of the science is accurate. There are two issues here: (i) the folding state of the t/Q-SNARE complex; and (ii), the zippering of the trans-SNARE complex.

\(i\) In the text of our original manuscript, we wrote: "In the \"half-zipped\" state, the neuronal t/Q-SNARE complex is structured to layer +4 (Ma et al., 2016), a result in precise agreement with the present experiments.\" This is correct. As the referee says, Ma et al. 2016 analyzed the isolated t/Q-SNARE complex (without an R-SNARE):

"Based on this inferred folding pathway, the positions of the partially zippered state 3 and the folded state 2 were mainly determined by their extensions relative to the extension of the unfolded state 4. The model fitting showed that the folded t-SNARE complex was largely a three-helix bundle with frayed C termini for both syntaxin and SN1. The boundary between the ordered and disordered regions lay approximately between the +4 and +5 layers ([Figure 1A](#fig1){ref-type="fig"} and [Table 1](#table1){ref-type="table"})."

They continue: "We derived a structural model for the t-SNARE complex in which the three SNARE motifs formed a three-helix bundle from −7 to +4 layers and were disordered from +5 to +8 layers."

\(ii\) The question then arising is whether this is actually the state of the t/Q-SNARE complex in a half-zipped trans-complex. Zhang et al., have repeatedly argued, based on multiple lines of evidence, that it is. Figure 1E from Ma et al. (2016, Cell Reports) shows their interpretation in graphical form. Note that in State 3, the partially or half-zipped complex, the t/Q SNAREs are structured to layer +4.

There's a very similar schema in Ma et al., 2015 *eLife* (by coincidence, also Figure 1E). In that paper Ma et al., write:

"In the partially-zippered state 3, the VAMP2 CTD and the t-SNARE CTD are [un]{.ul}folded from layer +8 to layer +3 and layer +5, respectively, whereas the remainder of the SNAREs are largely helical as in the four-helix bundle. This structure is consistent with that of a different trans-SNARE complex located on the yeast vacuole (Schwartz and Merz, 2009)." \[Emphasis added.\]

In independent force spectroscopy experiments, a metastable, partially-zipped intermediate was also reported, with the R-SNARE zipped to an ensemble of states from layer -2 to +2 and, again, the authors interpret their data as indicating that the t/Q-SNARE CTD is structured beyond the +2 layer (Min et al., 2013). Thus, the results in the literature are generally consistent between research groups, and are consistent with both our descriptions and our experimental findings.

Again, we thank the referee for prompting us to go back and take another look at these beautiful papers. Doing so has allowed us to improve both the Results and the Discussion.

> 12\) Figure 8D-E: The observation that SM proteins attenuate SNARE CTD zippering was previously reported for Munc18-1 in Ma et al., 2015. This finding is counter-intuitive, but is also consistent with the template model proposed by Baker et al.,.

This is a critical point and we thank the Referee for the reminder. The Zhang lab's laser tweezers experiments are consistent both with the Baker-Hughson Vps33 structures and with our fusion experiments. We now cite the Ma 2015 paper. Moreover, we now show that HOPS/Vps33 is ejected from the Qc-3∆ pre-fusion complex when Sec17 is added to trigger fusion (new [Figure 9A](#fig9){ref-type="fig"}).

> 13\) Discussion section: \"Fifth, Sec17 and SM proteins can simultaneously and cooperatively bind quaternary SNARE bundles, with the bound SM opposing Sec18-mediated SNARE disassembly\". It may be confusing to emphasize this point, because the authors stated earlier that SM proteins should be displaced for SNAREs to fully zipper. It is understandable that SM proteins protect the functionally important partially-zippered SNARE complex from pre-mature disassembly by Sec17 and Sec18. What\'s the biological function for SM proteins to protect the assembled helix bundle?

We have reason to suspect, but cannot yet say with certainty, that the C-termini of the SNAREs in the SM-Sec17-SNARE complex characterized in solution in Lobingier et al., 2014 are splayed (as in a trans- complex). If that were the case, SM-Sec17-SNARE complex might represent a docked-, trans-paired intermediate. We are working toward a more definitive characterization of this complex.

> 14\) Discussion section: \"First, Sec17 could stabilize the partially-zipped SNARE complex\". This sentence may be confusing. Stabilizing the partially-zippered SNARE complex would either promote initial SNARE zippering (relative to unzipped state) or hinder CTD zippering (relative to the folded four-helix bundle state), which contradicts the model shown in Figure 9. It seems that Sec17 stabilizes the folded four-helix bundle state.

Thanks for catching that. The sentence has been re-worded to clarify.

> 15). In subsection "HOPS selects the outcome of Sec17--SNARE interactions", the authors write \'Sec17 triggered fusion by pre-formed Qc-3∆ complexes in PEG reactions just as efficiently as in the HOPS reactions\', but the data in Figure 8D suggest that the HOPS reaction is actually quite slower. This could be an important result. What does it mean?

Here's the complete passage from the original submission (emphasis added):

\"Remarkably, Sec17 triggered fusion by pre-formed Qc-3∆ complexes in the PEG reactions just as efficiently as in the HOPS reactions. We conclude that HOPS not only accelerates tethering and productive trans-SNARE zippering, but allows these processes to occur in the presence of otherwise-inhibitory Sec17. Once the partially-zipped SNARE complex has assembled, however, HOPS (and its SM subunit Vps33) are dispensable. Indeed, the SM may need to dissociate from the trans-complex before C-terminal zippering can occur and membrane fusion can initiate, as suggested by recent Vps33-SNARE crystal structures (Baker et al., 2015). As expected if a rate-limiting Vps33 dissociation step is bypassed, Sec17 triggers fusion with \~5-fold faster kinetics when HOPS (and hence Vps33) are absent ([Figure 8D](#fig8){ref-type="fig"}).\"

As mentioned above, we present new results in [Figure 9A](#fig9){ref-type="fig"} showing that HOPS-SNARE docking complexes (which appear to be trans-SNARE complexes), upon Sec17 addition. As suggested in referees' point \#12 above, the reference to Ma et al., 2015 has also been added to this passage, which is revised to ensure that it's as clear as we can make it.

> 16\) When discussing the observation that Sec17 can inhibit fusion, the authors should consider the possibility that such inhibition arises because of binding of Sec17 to non-productive t-SNARE complexes, thus stabilizing these complexes and preventing SNARE complex assembly.

This is a plausible interpretation that has been suggested by others, as we point out, with citations, in the original submission. The revised Discussion section is now extended to address this point more fully.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The last sentence of the abstract and also the last one of the introduction suggest that they authors are uncovering the reason for the essential nature of SM proteins. However, the major concepts underlying this essential nature (the orchestration of SNARE complex assembly while protecting against disassembly by Sec18-Sec17) were already shown a long time ago by the Wickner lab.

We've deleted the last sentence of the abstract and the last sentence of the Introduction.

Obviously, variations on these concepts have been introduced to the literature previously, by several labs including Wickner's. For example, experiments done by the Rizo, Ungermann, and Merz groups were first to show that Vps33 is directly necessary and sufficient for HOPS binding to SNARE domains and SNARE complexes, and that Vps33 (or, similarly, Munc18-1) directly impair Sec18-medited SNARE complex disassembly, in the absence of the other HOPS subunits. Many other experiments relevant to these concepts have been done in other labs, and we cite papers from those groups as well. That said, sixteen papers from Wickner's lab were cited in the previous submission, and eighteen papers from Wickner's lab are cited in this submission.

> The authors do add another layer by providing evidence that HOPS prevents the inhibitory function of Sec17, which is interesting, but cannot be considered \'the observation\' that makes SM proteins essential.

We agree that this is one of the aspects of the biochemistry uncovered in our study. The phrase "the observation" does not appear in our manuscript. It does not represent our view.

> In this context, the importance of Wickner\'s work is also ignored in the third paragraph of the introduction. The authors should rephrase all these parts of the manuscript accordingly.

The third paragraph of the Introduction is a framing paragraph which orients readers to the general features of SM proteins. In the previous submission, we cited three excellent review articles that do in fact steer readers toward many of the Wickner group's papers (as well as key reports from many labs). We now cite two additional reviews that cover the functions of tethering factors: Angers and Merz, (2011), and Wickner and Schekman, (2008). In addition, we directly cite two pivotal research papers showing that SM proteins can directly stimulate SNARE-mediated fusion in vitro, in the absence of additional factors: Shen et al., (2007), and Furukawa and Mima, (2014). The following paragraph begins to describe the specific properties of Vps33; it cites the only paper ever co-authored by Wickner that assesses specific attributes of Vps33 (versus the HOPS holocomplex). We describe that work (Baker et al., 2015) as a "breakthrough." The referees' query served as a reminder that this paragraph would be a good place to cite papers on Vps33 from the Emr, Rizo, and Ungermann groups, as well. We now do so.

> In the results and particularly in the discussion, the authors argue against the idea that the N-terminal hydrophobic loop of Sec17 acts as a wedge to induce membrane fusion, but the argument is quite weak because it is based on the data acquired with one mutant (with the RSKSR sequence in the loop) that needs to be added at high concentrations to support fusion.

We agree. The interpretation is suggestive, not definitive.

Here is what we wrote in the Results section:

\"Notably, however, at very high concentration (10µM) Sec17-RMKLR had substantial stimulatory activity. This suggests that hydrophobicity in the loop contributes to Sec17 affinity but that the specific presence of aromatic residues (F21 and F25) is dispensable for Sec17 stimulation of fusion.\"

And in the Discussion section:

"Taken together, our findings here and in Song et al., (2017) suggest that the Sec17 hydrophobic loop increases Sec17 affinity, but that a "wedge" function is not strictly required for Sec17 augmentation of fusion."

In other words, we wrote that the data "suggest" an interpretation and summarized the evidence. It seems clear enough that the interpretation is provisional. To be even clearer, we have amended the text to:

"Taken together, our findings here and in Song et al., (2017) suggest that the Sec17 hydrophobic loop increases Sec17 affinity, but that a "wedge" function may not be strictly required for Sec17 augmentation of fusion."

> The authors previously published that Sec17 enhances SM protein binding to the SNARE complex, while now they propose that Sec17 dissociates the SM protein. This apparent contradiction was previously pointed out and was not properly addressed in the rebuttal letter or in the manuscript.

Our working model is that Sec17 and the SM can bind simultaneously to the SNARE complex, but only at specific stages of the docking and fusion cycle. Specifically, we suspect that Sec17 and the SM can bind simultaneously to the C-terminally splayed trans-SNARE complex, but that as the complex zippers the SM -- but not Sec17 -- must be ejected. The data shown in [Figure 9](#fig9){ref-type="fig"} are consistent with this working model, as are available structural data: the Hughson lab's structures of Vps33 and the Brunger group's structures of 20S particles.

We note that our current model is a modification of the model shown in Lobingier et al., (2014), because when we published that model, we did not yet know about the Baker and Hughson structures suggesting that SM ejection is a prerequisite for C-terminal zippering and fusion. [Author response image 1](#respfig1){ref-type="fig"} is part of Figure 9B of Lobingier et al.:

![](elife-27396-resp-fig1){#respfig1}

We now draw the model with the SM (red oval) dissociating prior to final SNARE zippering, as in the current [Figure 11](#fig11){ref-type="fig"}. Our current Discussion section says this:

"Third, the SM (HOPS/Vps33) is displaced when Sec17 is added to reactions with partially-zipped trans-complexes. As discussed above it is likely that SM displacement is essential for (and perhaps normally driven by) the completion of C-terminal zippering (Baker et al., 2015; Ma et al., 2016). We previously demonstrated that three Sec17 molecules and one SM (Vps33 or Sly1) can bind to a single SNARE complex (Lobingier et al., 2014). On a partially zipped trans-complex, a fourth Sec17 molecule might competitively displace the SM (Collins et al., 2005), facilitating the completion of SNARE zippering."

This working model does, of course, make lots of additional untested predictions and we are obviously working to test some of them.

For example, our working model predicts that structural analyses of a SNARE-Sec17-SM complex will reveal that the C-termini of the Qa- and R-SNAREs are splayed, as in the trans-configuration and similar to the SNARE configurations seen in the two Baker-Hughson co-crystal structures of Vps33 with either Vam3 or Nyv1. If these structures actually tell us what the SM-bound zippering intermediate looks like (and we think they probably do), it's evident that the SM cannot remain bound when the SNAREs fully zipper and fusion occurs. Sec17 does not have this limitation: as we describe in detail in the Discussion, Sec17 appears to be optimized to engage with either cis- or trans-SNARE complexes.

> There is no legend for Figures 7D, E.

This has been corrected.

> The title of Figure 9 is too strong as the conclusion is not really demonstrated by the data.

We agree. The title of [Figure 9](#fig9){ref-type="fig"} has been changed.

> The error bars in Figure 4 are plotted in a weird asymmetrical way as if the data are poorly fit. I would suggest a symmetric way to plot the error (mean with + and -- std or sem).

The error bars in [Figure 4](#fig4){ref-type="fig"} were plotted as mean + s.e.m., (not ± s.e.m.), exactly as specified in the legend for that figure. Because this caused some confusion, we have replaced the panels in [Figure 4](#fig4){ref-type="fig"} with new ones that show means ± s.e.m., and amended the figure legend accordingly.

[^1]: Four Letter Farm, Glide, United States.
